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Abstract
Chronic liver diseases, which includes alcoholic liver disease (ALD), are consistently
among the top 15 leading causes of death in the United States. ALD is characterized by
progression from a normal liver to fatty liver disease (hepatic steatosis), which can lead to
cirrhosis, alcoholic hepatitis, and liver failure. We have identified a novel role of phosphohistidine
signaling, mediated through phosphohistidine phosphatase 1 (PHPT1), in the onset of hepatic
steatosis. We have identified PHPT1 as a target of selective oxidation following acute ethanol
exposure as well as being downregulated following chronic ethanol exposure. We mapped the
oxidative modification site and developed a mass-spectrometry based phosphohistidine
phosphatase assay to determine the impact of PHPT1 oxidative modification during acute
ethanol exposure. To further understand the role of PHPT1 and phosphohistidine signaling
during chronic ethanol exposure, we have developed PHPT1 overexpression and knockout
mouse models. These mouse models were characterized using mass spectrometry-based
proteomics. They were then utilized in a 10-day chronic ethanol plus binge model to determine
the impact of PHPT1 expression on the onset of ethanol-induced hepatic steatosis. In addition,
advanced mass spectrometry-based phenotypic characterization was performed on the treated
liver tissues to determine the key regulators and canonical pathways influencing
phosphohistidine signaling during chronic ethanol exposure. We have evidence to suggest that
PHPT1 overexpression plays a protective role in the onset of hepatic steatosis, the PHPT1
heterozygous model is more susceptible to liver damage, and the complete knockout model is
embryonically lethal. Additionally, we have identified novel pathways and regulators involved in
phosphohistidine signaling during the development of ethanol-induced hepatic steatosis.
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Chapter 1 – Introduction
Alcoholic liver disease
Alcoholic liver disease (ALD) categorizes a plethora of specific conditions, including
fatty liver, steatohepatitis, and cirrhosis. In addition, patients are more susceptible to nonalcoholic related diseases such as non-alcoholic fatty liver disease, and chronic viral hepatitis
when developing ALD. A combination of these diseases, including obesity, significantly
increases a patient’s risk for developing cancer or liver failure. Alcohol can be contributed to
44% of all liver disease related deaths in 2003 [1], while liver cirrhosis was the 12th leading
cause of death in the United states in 2010 [2]. This is largely due to the prevalence and
socioeconomic burden of alcoholism. The consumption of ethanol can be traced back for
centuries when fermentation was necessary for disinfection [3]. Alcohol is a psychoactive drug
which means it alone can lead to dependence. It has been classified by the World Health
Organization to be among the top five leading risk factors for disease/disability and death in
2011 [4, 5]. In 2013, alcohol was number 4 of the 10 leading level 3-risk factors in developed
countries for both sexes in terms of attributable deaths, years of life lost, years lived with
disability, and disability-adjusted life-years [6]. Alcohol use, in general, accounted for 2.8 million
deaths in 2013 which was an increase in total and percent deaths from previous years [6]. The
wide prevalence of alcohol use, as well as its great burden of disease and death around the
world is the sole contributor to the development of alcoholic liver disease.
Alcohol consumption is generally classified by binge, chronic, or moderate consumption.
The National Institute on Alcohol Abuse and Alcoholism (NIAAA) classifies binge drinking as
bringing one’s blood alcohol concentration (BAC) greater than or equal to 0.08 g/dl. This is also,
classified by the Substance Abuse and Mental Health Services Administration (SAMHSA) as
1

having more than 4-5 drinks in one day or occasion. Chronic drinking is considered by the
SAMHSA as having more than 4-5 drinks in one occasion 5 or more times over a 30-day period.
Moderate or low risk consumption is considered anything less than binge drinking in a single
day or 7/14 drinks per week for women/men, respectively. Although actual consumption may
vary amongst individuals, these consumption classifications are widely used to classify different
models of consumption and their effects on disease progression. Chronic and binge drinkers are
considered most at risk for disease development. Alcohol has been linked to disease
development in almost every organ system in the human body. This includes gastrointestinal
complications in the stomach, pancreas, and colon, as well as heart disease and muscle
degeneration [7]. The brain and the liver however, are the two most commonly discussed
organs associated with heavy alcohol consumption. The brain is probably the most effected
organ given that changes in judgement can occur with a BAC as low as 0.02 g/dl, followed by
impairment of motor functions and reaction time occurring between 0.06-0.10 g/dl, with cognitive
ability and involuntary muscle impairment setting in around a 0.15-0.20. A BAC higher than this
is associated with immediate permanent brain damage and can also result in death. The other
main organ directly affected by alcohol consumption is the liver. As the main filtration system for
removing alcohol from the blood stream, the liver undergoes a great amount of ethanol-induced
stress in both chronic and binge drinkers. ALD is generally a progression from mild and
asymptomatic, to severe and life threatening (Figure 1).
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When it comes to disease progression, moderate consumption rarely leads to any
disease onset. However, it is estimated that 90% of individuals who are considered chronic
drinkers will develop steatosis [8]. This is classified by the enlargement of the liver and
histologically by the presence of lipid droplets in the hepatocytes. This injury can also be
accompanied by inflammation, which usually suggests a more severe condition developing. If
drinking persists 35% of those individuals will progress to steatohepatitis and up to 20% will
develop liver cirrhosis without first experiencing steatohepatitis. Steatohepatitis shows more
exacerbated symptoms to that of steatosis, with the increase in size and quantity of lipid
droplets, development of inflammation, hepatocyte necrosis, as well as Mallory bodies [9]. Up to
70% of those who do not abstain from alcohol following development of steatohepatitis will
progress to cirrhosis. Even of those that do abstain after the development of steatohepatitis only
roughly 27% will recover fully to a normal liver, whereas 18% will develop cirrhosis regardless
[10]. Cirrhosis is characterized by the deposition of extracellular matrix proteins via the onset of
widespread fibrosis and inflammation throughout the liver. This condition is also accompanied
by hepatocellular necrosis and predominantly macronodular development [9].
Disease prognosis depends on the stage of progression with fewer viable options as the
severity increases. If caught in the early stages of steatosis and fatty liver development, the
conditions are completely reversible with abstinence. However, the likelihood of full recovery
decreases with steatohepatitis and once cirrhosis begins to develop complete recovery from
abstinence alone is rare. Generally, treatment with corticosteroids or pentoxifylline is necessary
once the disease has progressed to steatohepatitis [11, 12]. These treatments are also limited
in their effectiveness. In many cases the only option for full recovery is a liver transplant. To
receive a transplant, the patient must be able to prove at least 6 months of abstinence to be
placed on the waiting list. The patient could then potentially wait years for a liver from a
compatible donor to become available. In addition, liver transplant surgery has its own risks,
with potential physiological rejection of a donor liver. These conditions make it very difficult for
3

patients with late stage ALD to fully recover, often requiring them to undergo regular blood
transfusions to overcome symptoms associated with decreased liver function. Furthermore,
with development of cirrhosis comes an increase in likelihood for liver cancer and malignancies
that can cause complications elsewhere. Ideally, prevention and early identification of this
disease is best. Prevention can obviously be accomplished through absolute abstinence or even
moderate drinking. In addition, a diet with high antioxidants has also been shown to play a
protective role in disease onset [11]. Unfortunately, early detection is difficult because often,
fatty liver disease is asymptomatic and can only be confirmed with a histologically stained
biopsy [13]. This makes identifying circulating biomarkers and molecular determinants of
disease critical for treatment. Disease onset is further complicated by the multiple mechanisms
involved in disease pathogenesis.
Ethanol pathogenesis involves a plethora of pathways and cellular response activated
following consumption (Figure 2). In addition, the expression level and effectiveness of these
pathways change as consumption increases. This coincides with the higher correlation in risk
factors seen in chronic drinkers, as compared to moderate. Initially, ethanol is primarily
processed and metabolized in the liver. Only about 10% of ethanol consumed is lost directly
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through sweat, lung, and kidneys [14]. Hepatocytes are the resident cells of the liver that
primarily metabolize ethanol due to their expression all three of the enzymes essential for
ethanol metabolism. Catalase is one of these enzymes, however, it is strictly expressed within
peroxisomes [15], so ethanol metabolism is primarily mediated by alcohol dehydrogenase in the
cytosol and cytochrome P450 2e1 (CYP2E1) within the endoplasmic reticulum (ER) [15-17].
Both enzymes yield acetaldehyde from the reaction, as well as generate the reduced form of
nicotinamide adenine dinucleotide (NAD+/NADH), and nicotinamide adenine dinucleotide
phosphate (NADP+/NADPH), respectively. The presence of acetaldehyde can lead directly to
stress on the cell in the form of reactive oxygen species (ROS). Acetaldehyde and ethanol are
directly involved in the creation of ROS such as hydrogen peroxide (H2O2) and superoxide anion
(O2-) [18]. Fortunately, acetaldehyde is converted into acetate by aldehyde dehydrogenase
which has high expression in hepatocytes and results in the creation of an additional NADH.
Initially, CYP2E1 only accounts for 10% of ethanol metabolism, but is substrate induced and
increases expression in chronic ethanol users [16, 17]. In addition, high frequency of ethanol
metabolism leads to an accumulation of NADH. This not only inhibits aldehyde dehydrogenase,
which results in more ROS via acetaldehyde accumulation, but also interferes with the citric acid
cycle (the main route for acetate metabolism), causing an overall increase in acetyl-CoA present
in the cell [13]. Both increased ROS production and acetyl-CoA accumulation will cause
significant downstream influences on hepatocyte function.
The presence of hydrogen peroxide and superoxide anion (known ROS) can create
even more hazardous free radicals and ferric oxide ions [19]. These highly reactive species lead
directly to protein oxidation, and cause stress on organelles, like the ER and the mitochondria.
The primary source of protection against ROS are free radical scavenging proteins such as
glutathione, epoxide hydrolase 1 (EPHX1) [20-23], and heme oxygenase-1 (HO1) in the ER
[24]. When ethanol exposure continues, however, the protective role of these proteins becomes
diminished, as they are oxidized leaving the cell susceptible to oxidation-mediated damage.
5

ROS is directly created in the ER through CYP2E1 metabolization of ethanol, resulting in
acetaldehyde formation. Protein oxidation in the ER can lead directly to accumulation of
unfolded proteins. The cell reacts by activating NF-κβ and JNK, leading to an inflammatory
response [25, 26]. In addition, unfolded proteins can stimulate the phosphorylation of Interferon
regulatory factor 3 (IRF3), which will stimulate mitochondrial stress via caspase activation [27].
These insults, will further activate the steatogenic pathway through sterol regulatory
element-binding protein (SREBP) activation, specifically SREBP1c [28, 29]. This pathway is
primarily regulated by adenosine monophosphate-activated protein kinase (AMPK) signaling,
which is inhibited directly by ethanol and acetaldehyde and indirectly via TNF (Tumor necrosis
factor) signaling [30]. TNF is released from adipose tissue following ethanol-mediated
inflammation [31]. Inhibition of AMPK activates SREBP1c and inhibits protective regulators,
such as peroxisome proliferator-activating receptor α (PPARα) and the RXR-α pathway [13, 3234]. This alteration in lipid homeostasis results in an increase in lipogenesis, via SREBP1c
activation of fatty acid synthase (FASN), and a decrease in lipid oxidation, which is necessary
for export. This outcome is additionally accompanied by an increase in acetyl-CoA present due
to inhibition of the Krebs cycle. This is mediated through the inhibition of isocitrate
dehydrogenase due to the NAD+/NADH imbalance in the cell. The resulting accumulation of
citrate is then exported back into the cell in the form of acetyl-CoA by ATP-citrate lyase (ACL),
which is regulated by a phosphohistidine modification [35]. This influx in the acetyl-CoA pool is
not only utilized for fatty acid synthesis, but it is also needed for protein acetylation. Histone
acetyl transferases (HATs), such as EP300, are stimulated by an increase in the acetyl-CoA
pool. This results in an increase in histone acetylation, which is known to activate protein
transcription. Concurrent pressure on the cell to increase lipogenesis, decrease fatty-acid
oxidation, and increase transcription leads directly to the onset of fibrosis. Consistent activation
of these pathways results in the disease progression from fatty liver/steatosis to more severe
steatohepatitis and cirrhosis.
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Phosphohistidine phosphatase 1
Phosphatases and kinases have been widely studied in mammalian and other cellular
models. These enzymes are responsible for the addition or removal of phosphate molecules to
protein targets. This modification has been shown to be a major player in a plethora of cellular
pathways, including cell metabolism, signal transduction, and transcription initiation. The most
familiar forms of phosphorylation occur on threonine, tyrosine, and serine residues. Their roles
in numerous cascades and protein function alterations have been widely studied and examined.
The significance of phosphohistidine, however, has been relatively uninvestigated. The gap in
knowledge around this modification can be mostly attributed to its unstable nature and
challenges in isolation, rather than its possible limited importance in cellular function when
compared to other well-investigated residues. The importance of phosphohistidine is already
highlighted in the few, yet critical targets that have been identified to date. Phosphohistidine was
first identified as an enzymatic intermediate for phosphoryl group transfer between enzymes
[36]. It has further been identified as a lasting modification which regulates targets such as ATPcitrate lyase (ACL) [35], G-protein (β subunit) [37], Histone H4 [38] and KCa3.1 [39]. The
development and loss of this modification on these targets can be attributed to phosphohistidine
kinases and phosphatases. However, to this date, only a few of them have been identified in
mammalian cells. Examples of these include nucleoside diphosphate kinase (NDPK), which has
phosphohistidine kinase activity [40], as well as phosphohistidine phosphatase 1 (PHPT1) [41]
and others [42].
PHPT1 is a 14kDa protein identified in porcine liver in 2002 with phosphatase activity for
phosphohistidine residues [41]. It has also been shown to poses dephosphorylation activity for
phosphoramidate [43] and phospholysine in vitro [44]. PHPT1 regulation of phosphohistidine
levels include activation/deactivation of known phosphohistidine targets. PHPT1 expression has
been linked to ACL function in multiple studies. Human-PHPT1 overexpression in murine
neuroblastoma cells was shown to decrease ACL activity and lead to a decrease in cell viability
7

[45]. However, the same group showed two years later that siRNA-mediated knockdown of
PHPT1 decrease ACL expression in pancreatic β-cell islets, and PHPT1 expression had no
impact on cell viability [46]. Although, these studies seem conflicting, they do show PHPT1
expression to be an important regulator in ACL function. In addition, PHPT1 was also shown as
an important regulator in the activation of G-protein during nutrient-induced insulin secretion
[46].They showed that siRNA knockdown of PHPT1 reduced glucose-induced insulin secretion,
but had no effect on KCL-induced secretion. This finding suggests PHPT1 was involved in Gprotein-signaling steps to mediate insulin secretion. It is known that G-protein has a key
phosphorylation site at His266 that is a target of NDPK and PHPT1 [47]. Although the
significance of this modification is not fully understood, it is believed to be necessary for Gprotein β/γ coupling to activate the holoenzyme [37]. PHPT1 plays an inhibitory role in the KCa
3.1 potassium ion channel where histidine phosphorylation is necessary for the channels
activation [39]. Histone H4 regulation is unknown but it has been identified as a target for
PHPT1 in vitro in many studies [38, 43, 48].
It is clear that PHPT1 and phosphohistidine are not involved in just a singular pathway in
mammals. PHPT1 is part of the Janus family of proteins and is the only phosphohistidine
phosphatase part of this family identified to date. This characterization is according to the family
domain classification available on the universal protein resource (uniport.org). The Janus family
proteins are best characterized by their involvement in sex differentiation in Drosophila
melanogaster [49]. PHPT1 and NDPK have been identified as players in disease progression as
well such as hepatocellular carcinoma (HCC), meningiomas, and lung cancer [50-53]. However,
the role of PHPT1 in each disease does not coincide across all conditions and cell types.
PHPT1 knockdown in lung cancer cells resulted in an inhibition of migration and invasion
mediated through actin cytoskeletal rearrangement modulation [51]. PHPT1 expression was
shown to be elevated in HCC tissues as well as in meningiomas [52, 53]. In HCC, siRNA
mediated knockdown of PHPT1 resulted in an increase in apoptosis and inhibited cell
8

proliferation as the G1-S phase transition [52]. In addition, according to The Cancer Genome
Atlas, PHPT1 has been shown to be amplified in multiple cancers, most notably in
neuroendocrine prostate cancer (Trento/Cornell/ Broad, 2016) and pancreatic cancer (UTSW
cancer center). PHPT1 seems to be influencing many different pathways in the cell which gives
insight into the significance of the phosphohistidine modification itself.
Phosphohistidine signaling
The phosphohistidine modification was initially published in 1962 and first described in
bovine mitochondria [36]. Since this time, there has been relatively little investigation in the
significance of this modification in mammals as compared to tyrosine, threonine, or serine
phosphorylation. This finding is in spite of the fact that it has been estimated that
phosphohistidine accounts for 6% of protein phosphorylation in eukaryotic cells [54], which is
two-fold more abundant than phosphotyrosine [55]. The main reason for the disparity in study of
this modification is its hydrolytic lability which is much higher than the better studied forms of
phosphorylation. This makes the modification very unstable in neutral conditions and even more
so in acidic environments, with a half-life of less than 30 seconds in 1M HCL [56]. In addition,
the modification can occur in two different conformations, at the 1N or at the 3N, of the
imidazole ring on histidine (Figure 3). The first discovery was on the 1N of the ring where it

played an intermediate role carrying a phosphoryl group between a substrate and the
phosphate donor on kinases and phosphatases [36]. This conformation has functioned in this
manner in many cases [56, 57]. The 3N location however has been identified as the location of
9

the lasting modification that influences enzymatic activity on known targets such as ACL [35],
G-proteinβ [37], and KCa3.1 [39], in addition to two component histidine kinase
autophosphorylation that occurs in Escherichia coli in vivo, and on Suc-AHPF-pNA and H4 [38]
in vitro. The function of phosphohistidine has been best characterized in bacterial and plant cells
[58], and their two component histidine kinase systems are well known for their regulation of cell
signaling and transcription[59]. Most of these studies, however, have investigated
phosphohistidine in a targeted manor. Targeted investigation is necessary because standard
cell lysis procedures, as well as mass spectrometry sample preparations, call for acidic
solutions and can result in complete loss of the modification before measurements are taken
[60]. Although these pathways are not present in mammalian cells, studies have shown
phosphohistidine levels to be significantly altered in diseases, including cancer, and to be
involved with a diverse list of pathways [61]. Recently, the development of pan-phosphohistidine
antibodies and phosphohistidine sensitive protocols have allowed the significance modification
to be further investigated.
Structure
To date there have been three main studies on the structure of PHPT1 and the residues
involved in substrate binding [57, 62, 63]. All studies have shown the primary and crystalline
structure of PHPT1 being highly conserved between mammals (Figure 4). The secondary
structure is composed of six β-stands, which are flanked by two α-helices and short
unstructured regions at the C- and N-terminals, 4 and 5 amino acids long, respectively [54].
Mutagenesis and NMR studies identified H53A in human PHPT1 to be catalytically inactive [56].
Other mutations that resulted in a significant decrease in kcat were M95D, A96D, K21A, and
S94A [56]. It was concluded that the substrate binding site was located at α1 and β4 on one
side and α2 and β5 on the other [55]. The residues involved directly in this region were Glu51,
Tyr52, His53, Try92, and Met95 [55]. Ser94 was determined to assist with phosphate
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stabilization via the -OH side chain [55]. His53 was determined to be the bound amino acid
during phosphoryl group transfer between substrate and donor [54-56]. In addition, the His53
was shown to stabilize the binding site via H53A mutagenesis causing destabilization of this

area [62]. All studies showed H102A mutagenesis to influence substrate binding as well, even
though it is located far away from the binding region [54-56]. This influence was determined to
be a result of its location in a highly hydrophobic core region of the protein. H103A-mediated
destabilization of the core region, had global protein conformational consequences resulting in a
decrease in catalytic efficiency [55].
Unfortunately, these studies were limited to PHPT1 function toward peptide or molecular
substrates, and not full protein interactions. Additionally, there have been no studies
investigating the binding mechanism of PHPT1 toward the N-ε-phosphorylation of lysine which it
was recently determined to target [44]. The influence of post-translational modifications on
PHPT1 activity is relatively uninvestigated. To date, only two modifications have been
characterized on PHPT1. One of these is an N-terminal protein acetylation [64] that occurs on
PHPT1 following N-terminal methionine cleavage. The other modification, which was
characterized in this dissertation, is Met95 oxidation which occurs via oxidative stress [65].
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Initial hypothesis of alcoholic liver disease pathogenesis
As discussed previously (Chap. 1 Alcoholic liver disease), there are multiple pathogenic
pathways involved in the onset of the ALD. The main pathways include oxidative stress that
causes an accumulation of ROS and can directly cause necrosis and apoptotic cell death. In
addition, the influx of acetyl-CoA, as well as signals from adipose tissue, lead to an increase in
lipid synthesis and a decrease in fatty acid oxidation. This change results in lipid accumulation
and the ethanol-induced hepatic steatosis phenotype. Both ROS and lipid accumulation
contribute to an increase in inflammation and protein transcription. This phenotype contributes
to the development of more severe conditions, such as cirrhosis or hepatocellular carcinoma via
cell differentiation. Many players in these pathways are known but progression and mechanism
of development still needs to be further investigated. Our investigation aims to identify novel
players in the onset of alcohol-induced hepatic steatosis and determine the mechanism in which
they are involved in disease progression.
A known key player in ethanol metabolism, ACL, is responsible for the conversion of
citrate into acetyl-CoA and oxaloacetate, and the reverse reaction. This reaction is necessary
following accumulation of citrate caused by citric acid cycle inhibition, which can come from
chronic ethanol ingestion that creates a high ratio of NADH:NAD+. In the later instance, the
synthesized oxaloacetate can be converted into malate by cytosolic malate dehydrogenase,
which utilizes the high concentration of NADH available to create NAD+. Malate can then return
back to the citric acid cycle within the mitochondria and be oxidized again to oxaloacetate to
maintain the function of the electron transport chain. This conversion prevents further
accumulation of NADH, but results in additional accumulation of acetyl-CoA. Acetyl-CoA
accumulation leads directly to fatty acid synthesis as well as histone acetylation. This result in
combination with ROS-induced inhibition of fatty-acid oxidation results in the lipid accumulation
responsible for the ethanol-induced hepatic steatosis phenotype. ACL is known to be
transcriptionally induced by insulin and glucose. These molecules simultaneously activate the
12

PI3K/Akt pathway which is known to phosphorylate and activate ACL. In addition, PHPT1
overexpression and siRNA-mediated knockdown models have been shown to directly impact
ACL activity. ACL is a known target of phosphohistidine modification and PHPT1
dephosphorylation.
Our initial hypothesis was that the regulation of ACL by PHPT1 was being influenced
following acute or chronic ethanol exposure. We hypothesized that ethanol-induced factors such
as ROS were altering PHPT1 activity via modification or expression levels which decreased
regulation of ACL. Furthermore, we wanted to investigate the role of PHPT1 in the onset of
alcohol-induced hepatic steatosis. In addition to ACL, we believed there are many other factors
PHPT1 and phosphohistidine modification influenced that were involved in the onset of ALD.
Despite this, the role of PHPT1 and the significance of phosphohistidine signaling following
ethanol-induced hepatic steatosis has not been investigated. Although, as previously
mentioned, PHPT1 has been identified to be involved in other diseases, such as
neuroendocrine prostate cancer, and lung cancer [51, 66].
Other roles of PHPT1
Beyond the previously mentioned known targets, there have been many additional
suggestions into the role of PHPT1. As previously mentioned from a domain standpoint, PHPT1
fits in the Janus family of proteins. This family is best characterized in Drosophila melanogaster
as being involved in sex differentiation and development. It is likely that PHPT1 plays a role in
cell differentiation in mammals as well. This theory is further supported by PHPT1 being linked
to cancer development in multiple studies. In lung cancer, it is believed to be involved in cell
migration through actin cytoskeleton rearrangement. Furthermore, the expression of PHPT1 in
lymph nodes and lung cancers correlated with the severity of the cancer from human samples
[51, 66]. PHPT1 is believed to be influencing tumor progression through NF Kappa B signaling
pathway by inducing MMP9 [67]. These studies suggest that PHPT1 plays a major role overall
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in cancer progression and cellular homeostasis although there are no currently known targets to
suggest this.
In addition, relatively little is known about PHPT1 regulation. Studies have shown broad
expression regulators, such as HNF4α, to influence PHPT1 expression [68]. HNF4α is a key
regulator of many proteins involved in lipid homeostasis [69]. These include the PXR and RXR
pathways, which interact with the acetyl-CoA pool and contribute to fatty acid metabolism [70,
71]. PHPT1 may be involved in this regulation through its interaction with ACL or other unknown
targets involved in lipid metabolism. In addition, expression levels have also been shown to
correlate with phosphohistidine kinases, such as nucleoside diphosphate kinase-B (NDKB) [72].
NDKB is also known to be a transcriptional regulator of MYC, a well-known oncogene [73].
Phosphohistidine kinases are best characterized in two component histidine kinase systems in
prokaryotic cells. These systems are also vital in signal transduction, resulting in transcriptional
activation [59]. Furthermore, both histone H4 and H1 have shown to be targets of PHPT1 in
vitro [43, 44]. PHPT1 has been shown to dephosphorylate H4 and have phospholysine activity
to dephosphorylate H1 in vitro. PHPT1-mediated histone dephosphorylation has potential to
widely influence protein expression. It is well known that transcription can be mediated through
a plethora of histone modifications. However, the impact of these modifications and full
characterization of PHPT1 regulation has not been elucidated.
Proteomics & alcoholic liver disease
As previously mentioned, ALD can develop in many ways, and monitoring its
progression in a patient and a model is difficult. To properly investigate the onset of this
disease, as well as elucidate pathways involved that have yet to be discovered, it is necessary
to use an approach that will both, provide information about known disease states, and
unbiased information for discovering novel players. A key indicator of cellular functions and
disease state is protein expression levels. Protein expression data provides a snapshot of the
genes that have been activated, as well as PTMs that may be influencing activation. These data
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differ from genetic information, such as DNA or mRNA, that only show the potential expression
profile. In the case of ALD, the expression levels of key proteins such as epoxide hydrolase
(EPHX1) and cytochrome P450’s (CYP2E1) are critical indicators for onset of hepatosteatosis
[24]. Other proteins such as the PPAR family (α, β, and γ), the LXR or RXR proteins, or
inflammatory proteins like cytokines or JAK/STATS, provide critical information about the
severity of the disease and the mechanism of onset. Therefore, to thoroughly study this disease,
we must be able to identify these proteins and their abundances in an accurate and
reproducible manner. However, to elucidate new mechanisms involved in disease progression,
our approach must also remain unbiased toward known targets. To obtain measurable and
reproducible unbiased data regarding the global proteome expression levels, we will utilize
mass spectrometry-based proteomics techniques. Specifically, shotgun proteomics using datadependent acquisition, followed by label free quantification of purified tryptic peptides from
samples lysates, to determine significant protein expression changes between treatments.
Mass spectrometry and proteomics.
Initial proteomic studies involved 2D separation gels, which would discriminate proteins
based on their molecular weight on one axis and the isoelectric point on another axis. This
technique allowed sufficient separation of proteins in a lysate to determine expression difference
of a single protein or protein group between treatments. It would then be required to determine
the identity of each protein recognized as differentially expressed. This process could be done
by extracting the protein or protein group, purifying, and performing an NMR or mass
spectrometry analysis of each. This method was tedious and highly objective in determining
which protein groups differed between treatments. Given the recent advances in mass
spectrometry, and the ability to pair with separation methods, such as liquid or gas
chromatography, mass spectrometry-based proteomics has now become a highly accurate,
high-throughput method.
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Advances in instrumentation have enabled the use of mass spectrometry to investigate
molecules faster and of varied sizes and complexities. Both time-of-flight (TOF) and Orbitrap
instruments have provided significant advances in resolving power, resolution, and mass
accuracy of multiple charged ions, such as peptides and proteins. These advances in detection
methods are paired with the creation of hybrid instruments which allow more accurate
quantification with less interference from neutral molecules or undesired ions. Hybrid
instruments incorporate a multi-stage system that maximizes ion detection efficiency using ion
optics to focus and normalize ion beams and velocity, followed by multi-pole (quadrupoles and
octupoles) stages, which create mass and ion filters and further stabilized ion beams, prior to
entering main or secondary detection components. The addition of a linear ion trap can allow
simultaneous MS/MS filtration and detection, while the primary detector such as an Orbitrap is
performing full-scan detections. MS/MS has also been improved for proteomic purposes. There
now exists a plethora of MS/MS dissociation techniques that can break specific bonds of the
investigators choice. Additionally, MS/MS is no longer limited to MS2, and multiple instruments
can perform MSn where n is limited typically by the abundance of the molecule being
investigated. The advancements in instrument ionization methods also enhanced mass
spectrometry-based proteomics. Specifically, the development of electrospray ionization (ESI),
paired with liquid chromatography, and matrix assisted laser desorption/ionization (MALDI),
make it possible for relatively easy ionization of complex protein samples for mass spectrometry
analysis. Continuing advances in instrumentation and ionization methods are making mass
spectrometry-based proteomics a highly accessible field.
Another key aspect that has allowed mass-spectrometry to become the go-to method for
proteomic analysis is the pairing with liquid chromatography [74]. Liquid chromatographs (LC)
use pumps and filtered columns to create separation of a sample on the molecular level,
creating a stable and reproducible gradient of molecular influx in-line with the mass
spectrometer. This technique is performed using sold phase and liquid phase separation. In the
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case with proteomic studies, the liquid phases are an aqueous buffer (hydrophilic) and an
organic buffer (hydrophobic). The solid phase is usually carbon chains of specified length and
density which bind to the proteins/ peptides present in a complex sample. Peptides that are
highly polar and most soluble in the aqueous phase will not bind to the solid phase (column) and
be the first to flow through in a reverse phase column set-up. Coinciding with MS detection, the
LC will increase the ratio of organic: aqueous liquid phase, creating a gradient. This gradient will
allow increasingly polar peptides to solubilize and release from the column for mass
spectrometry identification. In-line LC allows for stable peptide influx, preventing the instrument
from being overwhelmed with numerous peptides simultaneously, and provides a reproducible
polarity-based gradient for reference. Liquid chromatography, paired with an ESI source, has
made it possible to analyze a complex protein mixture efficiently and accurately. Advancements
in liquid chromatography, including high-pressure and ultra-high pressure (HPLC and UHPLC)
systems, have allowed for even more efficient separation of peptides and higher degrees of
reproducibility in liquid chromatography-paired mass spectrometry (LC-MS).
Numerous advancements in mass spectrometry have made it the ideal instrument for
proteomics studies. In our studies, we will be utilizing LC-MS for label free quantification of cell
lysates, individual proteins, and animal tissue lysates. This method will allow us to identify and
quantify proteins present in these tissues in a reproducible and accurate manner. The primary
instrument utilized will be a hybrid quadrupole-Orbitrap instrument (Q-Exactive Plus, Thermo),
using a top 10 data-dependent acquisition method. Further information on the exact
specifications of this instrumentation will be included in the respective methods sections.
Label free quantitation
The process of protein quantification begins with the sample preparation immediately
following protein purification. Following lysis and protein purification, protein concentrations are
determined from each sample and standardized across all samples being analyzed. For our
studies standard protein quantities (between 100-200 µg) are then added to filter-aided sample
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preparation (FASP) columns to undergo buffer exchange and trypsin digestion, as described
previously [75]. The purpose of the buffer exchange is to remove the detergents, which were
used for lysis, that cause interference with LC/MS analyses. This exchange is accomplished
using 8M urea as a wash buffer to keep the proteins solubilized. Then, all proteins are reduced
to break disulfide bonds and immediately alkylated to prevent unwanted reactivity of free thiol
groups. These modifications assure that all proteins are denatured and help insure the complete
digestion by trypsin. Following modifications, another buffer exchange takes place to allow for
trypsin function in ammonium bicarbonate. Trypsin digestion occurs at 37° C overnight, creating
peptides that are either lysine or arginine-terminated. This digestion also allows the peptides to
now flow through the filter. Peptides then must undergo a desalt procedure. Salt analytes
interfere with ionization efficiency and can create adducts that change peptide masses and
interfere with quantification. The desalt procedure is concluded with elution by acetonitrile,
which is then placed under a vacuum until dryness. Samples are resuspended in 0.1% formic
acid in water at a concentration of 1-5 µg/µl. There are a variety of other sample processing
methods available including, in-solution and in-gel digestions, but most methods apply the same
chemical manipulations of reducing, alkylating, and digesting proteins to produce purified
peptides in a slightly acidic solution.
Samples then undergo LC-MS analyses consecutively, using the same procedure,
column, and ESI tip for each sample to ensure reproducibility. Instrumental standards are run
before and after samples for quality assurance. Samples are run with either technical or
biological replicates as well. LC-MS analysis provides qualitative information of individual
peptide masses, as well as quantitative information of peak intensities relative to the noise level.
In addition, MS/MS data provides peptide backbone information that can be used to identify
specific amino acids and modification on each peptide. This information is then searched
against the known proteome database to match the identified peptide peaks in the MS data with
known proteins.
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In our studies database peptide identification is performed using the MaxQuant
(maxquant.org) search algorithm to determine peptide identifications and quantity. Peptide IDs
are determined using a 0.01% false discovery rate to guarantee accurate protein recognition.
This algorithm quantifies the protein abundances by converting the relative peptide intensities
originating from the same protein into label free quantification intensities. This calculation is
done following peptide identification across all samples and replicates. The algorithm then
assumes most protein abundances should remain constant across all samples, regardless of
treatment type. In addition, the algorithm considers the number of peptides (unique and
repeated) identified that relate to each protein, as well the total intensity of all the peptides from
the same protein. Using these factors, MaxQuant creates a label free quantification (LFQ)
intensity which is then used for quantification, in lieu of the absolute intensity of each peptide
provided by the LC-MS raw data. LFQ peptide count cut-offs are set to 1 to minimize lost
intensities with a majority of the calculated LFQ intensities being within a few percent of the
absolute intensity values. The LFQ values are then used to compare control and treatment
samples and to determine significant differentially expressed proteins. Label free quantitation
has been shown to be a reliable method for comparing protein expression from multiple
samples to each other [76]. To further strengthen the confidence in the LFQ method, the use of
multiple (n≥3) technical or biological replicates is necessary.
Proteomic studies using animal models
The primary animal model used in these studies has been Mus musculus. The mouse
model provides more biological relevance than mouse or human cells alone. The homogeneity
between mice and human organ functions and systems, combined with their short lifespan and
quick reproductive cycle, make them an ideal candidate. Mouse models of alcoholism have also
already been well developed and characterized [77, 78]. The primary mouse strain we used was
the C57BL6/J mouse which has been widely used in the 10-day chronic ethanol plus binge
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model. This model has been shown to induce severe hepatosteatosis apparent by the
development of lipid droplets and inflammation [77].
Further validation of this model and the disease state is accomplished through mass
spectrometry-based proteomics. Proteome-wide LFQ quantification of differentially expressed
proteins between the treatment and controls groups will identify proteins significantly changed
during disease onset. This method has been validated against known proteome changes such
as increase in expression of CYP2E1 and EPHX1 [24], as well as other indicators of
hepatosteatosis [77]. Using proteomics in combination with an organism physiologically similar
to humans allows us a more accurate depiction of the disease state and cellular components
being influenced.
The other advantage of using a mouse model for proteomic disease analysis is that
proteome database for Mus musculus is available and well-annotated. This database is used to
identify the proteins discovered from mass spectrometry-detected peptides. A well-annotated
database is important to have in that it will provide more complete information about the proteins
identified rather than an abundance of uncharacterized proteins. The primary database used for
the mouse model searches is extracted from UniProt (uniprot.org) and updated regularly to
incorporate all recent annotations. These annotations are of additional importance following
identification and quantification, as they are used for mechanistic analyses as well. The
similarity of human and mouse cellular functions and pathways allows the protein expression
information to be employed for determining upstream and downstream regulators influenced by
the identified differentially expressed proteins. This analysis is a key step in elucidating novel
enzymes and mechanisms involved in the disease being investigated.
Significance of protein modification in alcoholic liver disease
Post-translational modifications can influence all aspects of protein function. There is a
plethora of modifications that can occur on an individual protein causing biochemical changes in
the proteins conformation. These modifications can directly impact protein function or
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expression, or indirectly impact a protein affecting its downstream targets or upstream
regulators. Ethanol can induce a wide variety of modifications through a direct manor with the
creation of ROS or an indirect manner through signaling mechanisms brought on by its
presence. Ethanol can lead to the creation of ROS such as acetaldehyde, hydrogen peroxide,
and free radicals. These are known to oxidize susceptible amino acid residues, such as
methionine, which often leads to loss of function [79]. This inhibition is observed in calmodulin
and interferon kappa B alpha, as well as other proteins [80-82]. Other modifications such as
phosphorylation, acetylation, and methylation are induced by ethanol as well. These
modifications are induced by the change in metabolism and cell signaling brought on by ethanol,
and they will further influence cellular function and protein expression.
Oxidative modification is the most prevalent PTM directly induced by ethanol [83].
Oxidation is notorious for causing loss of function and disturbing vital cellular functions [79]. The
presence of ROS is contested directly by anti-oxidants and hydroxylation enzymes such as
glutathione and epoxide hydroxylase [22, 84]. The role of these molecules is to hydrolyze the
oxidants preventing them from directly impacting vital proteins. In binge and acute models of
ethanol exposure, the presence of these molecules is initially decreased as they are
overwhelmed by the abundance of ROS present. However, in chronic models, the cell responds
to continual ethanol exposure by overexpressing oxidant scavengers such as EPHX1 [24]. Once
depleted, however, antioxidants initially present in the cell take time for replenishment, leaving
the cells more susceptible to ethanol-induced oxidative damage.
Other modifications are impacted as well following chronic ethanol exposure. A
consistent increase in ethanol metabolism will change the ratio of molecules involved in
glycolysis and the citric acid cycle. Ethanol must be metabolized by alcohol dehydrogenase and
then further by aldehyde dehydrogenase to prevent the presence of acetaldehyde [15]. This
reaction results in an increase of NADH molecules which can inhibit the activity of the citric acid
cycle. This stall will cause an increase in citrate in the mitochondria, which gets converted back
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into acetyl-CoA in the cytoplasm via ACL. An increase in the acetyl-CoA pool directly correlates
to acetylation of proteins, including histones, which will directly result in expression changes
[85]. Furthermore, abundance of acetyl-CoA can also dysregulate glycolysis and activate
alternative pathways for cellular metabolism. This effect leads to greater protein modifications
occurring, such as methylation, phosphorylation, and the previously mentioned oxidation and
acetylation [85]. Even minor changes in PTM’s of regulatory proteins like histones or MAPkinases will result in massive expression alterations [86]. Continuous ethanol exposure in a
chronic model will lead to irreversible expression changes via PTM’s and result in the
development of severe ALD [13].
Summary of approaches and project aims
The adverse effects of alcoholism on the human liver are well known. Chronic ethanol
consumption is strongly correlated to a unique pathology of liver diseases known as ALD. The
mechanisms and players involved in the onset and progression of this disease are still poorly
understood. Many of the proteins believed to be key regulators have been identified through
mRNA characterization or biased approaches targeted at individual proteins. Our study aimed to
identify and characterize a novel player in the onset of ALD through the global proteomic
analysis of an ethanol-induced hepatic steatosis models. An acute model study using HepG2,
hepatocyte-like cells, was performed and characterized using the SILAC approach to determine
expression and modification changes. This study identified a phosphohistidine phosphatase
(PHPT1) as being selectively oxidized but showed no change in expression levels following the
acute exposure. Further characterization of this modification and its influence on PHPT1 was
performed using mass-spectrometry based modification site mapping and a novel
phosphohistidine phosphatase assay.
In addition, a 10-day chronic plus binge mouse model was used to determine more
biologically relevant effects of long-term chronic ethanol exposure on the development of liver
injury. Following a global proteome characterization between ethanol and control diet-fed mice
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using high-resolution mass spectrometry, we identified PHPT1 as being significantly
downregulated by ethanol exposure. This discovery created the basis for the second and third
aim in determining the significance of PHPT1 expression prior to and following ethanol-induced
hepatic steatosis. To investigate this, we developed both a liver-specific overexpression model
and bred an organism-wide knockout model. Overexpression was accomplished using an
adenoviral-based vector delivery of PHPT1 paired with a liver-specific albumin promotor
administered intravenously through the tail. This yielded a significant increase in PHPT1
expression specifically in the liver, which lasted for multiple weeks. In addition, we requested
creation of a non-conditional PHPT1 knockout mouse through cre-mediated lacZ substation by
UC Davis. The heterozygous genotype yielded an average of 50% mRNA and protein
expression, compared to wild-type, in all tissues tested but displayed no obvious phenotypic
changes. All heterozygous crosses, however, did not yield a complete PHPT1 knockout
offspring. This result suggests that PHPT1 is critical for early development. Both models where
then characterized using mass spectrometry-based phenotypic characterization to determine
the mechanisms impacted by PHPT1 expression alteration.
Finally, both models were used in the 10-day chronic plus binge ethanol exposure model
to determine the influence of PHPT1 on the development of ethanol-induced hepatic steatosis.
Groups were pair-fed with a control (sucrose supplemented) or ethanol diet. Disease
progression was determined using liver sectioning histology and circulating aspartate
aminotransferase (AST), alanine aminotransferase (ALT), and triglyceride (TAG) levels. PHPT1
expression levels were determined using western blot and LFQ values from global proteomic
analyses. Finally, mass spectrometry-based phenotypic characterization was performed on liver
tissue from each mouse. This method was used to identify mechanisms and pathways
influenced by PHPT1 during chronic ethanol exposure. Conclusions of these studies provide
greater insight into the role PHPT1 and phosphohistidine signaling plays in the onset of ethanolinduced hepatic steatosis and potential contribution to the pathogenesis of ALD.
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Chapter 2: Structural and activity characterization of human PHPT1 after oxidative
modification
Summary
The structure and primary function of PHPT1 has been recently elucidated (Chapter 1
section) [57, 62]. However, the biological influence of PHPT1 phosphatase activity on cellular
functions and vice-versa are not fully understood. The number of confirmed targets of PHPT1
remain minute in comparison to the estimated 6% of the protein phosphorylation being
attributed by histidine phosphorylation [87]. Furthermore, the influence of post-translational
modifications (PTMS) such as phosphorylation or oxidation on PHPT1 have not been
investigated. Currently, only one PTM has been identified on PHPT1 and that modification,
being constitutive N-terminal acetylation [64], is the most common modification in eukaryotic
proteins [88]. The role of PHPT1 and how PTMs influence its activity and structure is necessary
to further characterize the significance of this protein. Specifically, we wanted to determine how
ethanol-induced PTMs influenced PHPT1 phosphatase activity givens its regulation of ATPcitrate lyase, a key protein in ethanol metabolism. This study was conducted by first creating an
acute ethanol exposure model with HepG2 cells, exposing them to high amounts of ethanol for
8-12 hours. This exposure led us to identify PHPT1 as a target of increased oxidation following
ethanol exposure. This acute exposure was recreated in vitro using the known reactive oxygen
species (ROS) hydrogen peroxide. Following treatment, we used mass spectrometry-based
modification site mapping to determine the exact location and quantify the percent of oxidized
PHPT1. For activity characterization, we used oxidized and non-oxidized PHPT1 in a mass
spectrometry-based phosphohistidine phosphatase assay and explicit solvent molecular
dynamics using computer simulations of the known PHPT1 structure with and without the
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oxidative modification. Our investigation found that PHPT1 can be selectively oxidized on Met95
located in the substrate binding region; however, the oxidation does not limit PHPT1
phosphohistidine phosphatase activity in vitro. This result suggested PHPT1 plays a more
complex role in ROS-mediated cellular response.
Introduction
Ethanol-induced reactive oxygen species
A large influx of reactive oxygen species (ROS) are present in hepatocyte cells following
acute and chronic ethanol exposure models. These ROS are generated both directly and
indirectly by ethanol metabolism. Ethanol leads directly to the generation of hydrogen peroxide
and acetaldehyde consequentially of ethanol’s metabolism. Acetaldehyde is directly created by
alcohol dehydrogenase and hydrogen peroxide, which can result from the natural
decomposition of ethanol in an intercellular environment [18]. Furthermore, both molecules can
lead to the creation of free radicals such as a superoxide radical and reactive nitrogen species
like peroxynitrite. This influx of radicals exacerbates the amount of ROS present in the cell. In
an acute model, oxidation is most likely to occur more readily due to the cell not having the
opportunity to increase expression levels of protective antioxidant, or hydroxylase enzymes, and
decrease the production of acetaldehyde via alcohol dehydrogenase [89]. In chronic exposure
models, ethanol metabolism is primarily performed by CYP2E1 as a consequence of alcohol
dehydrogenase inhibition due to an increase in NADH and acetaldehyde [90]. Additionally,
overexpression of protective hydroxylase enzymes occurs to reverse the effects of ROS [91].
HepG2 cells
HepG2 cells were derived from a a fifteen-year-old caucasian American male with well
differentiated hepatocellular carcinoma. The cells resemble immortalized human hepatocytes
and can be used to simulate liver experiments. HepG2 cells have been used previously to
investigate the liver metabolism of toxic reagents including ethanol [92]. However, given the
absence of expression of CYP2E1 and ADH1, these cell are not the ideal model for studying
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oxidative stress. Similar to hepatocytes, HepG2 cells express high amounts of albumin and
transferrin.
Oxidation modification
Oxidation modifications have been observed in a wide variety of proteins. This oxidative
modification can occur on methionine, tyrosine, tryptophan, or cysteine residues and can occur
as single, di- or tri-oxidation in some situations. An increase in the presence of ROS can lead to
an increase in global protein oxidation. These oxidants can lead directly to protein oxidation by
interacting with a susceptible residue or can increase oxidation indirectly by saturating
glutathione, and increasing CYP2E1 production in cells exposed to ROS over long periods of
time [89]. CYP2E1 activation leads to an increase in expression and results in the creation of
more NADP+. Reduction of NADP+ to NADPH leads directly to more ROS present in the cell.
Protein oxidation, especially on methionine residues, leads to inhibition of enzymatic function in
the well documented case of calmodulin and interferon kappa B alpha [81, 82, 93]. The
exception to this is with glutathione-S-transferase, which can be oxidized on multiple methionine
residues without any influence in activity [84]. PHPT1 has two methionine residues as potential
targets of oxidation (Met64 and Met95) and multiple other residues susceptible to oxidation
(cysteine, tryptophan, and tyrosine) as well. One methionine residue occupies the middle of the
substrate binding region of PHPT1 (Met95) and has been shown to be directly involved in
substrate binding region stability [62]. Due to the susceptibility of this residue to oxidation, its
importance in substrate binding, and the nature of the oxidative modification, we hypothesize
that if PHPT1 oxidation is selectively occurring at this residue, and PHPT1 phosphatase activity
will decrease as a result of oxidative modification.
Phosphohistidine phosphatase assay
Phosphohistidine is known to be an unstable modification in vitro. Therefore, the
development of a reliable phosphohistidine phosphatase assay is not trivial. Currently, the only
phosphohistidine phosphatase assays that have been used rely on phosphohistidine analogs
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that are more stable during the experiment. The benefit in stability, however, is accompanied
with a decrease in specificity. This compromise makes the assay less reliable when comparing
to in vivo results. Another phosphohistidine phosphatase assay developed relies on a malchite
green reporter molecule that is activated by the removed phosphatase group [48]. This method
requires the reaction to take place completely. This requirement makes it an indirect
measurement and does not allow reaction monitoring in real-time. We will aim to develop a
mass spectrometry-based assay utilizing a small histidine-phosphorylated peptide, which can be
identified and verified using MS/MS. In addition, the reaction can be monitored in real-time and
take place during direct infusion so any changes in phosphorylation can be seen immediately
following enzymatic activity. This novel assay will look directly at the phosphorylated and nonphosphorylated peptides and can be used to quantify the amount of each present in the sample
at each time point.
Modification site mapping
Post translational modifications are a wide variety of chemical additions than can occur
on many different amino acids. They can influence activity, signaling, and even protein
longevity. Mass spectrometry is a valuable tool used to identify these modifications. Using full
scan analysis of trypsin-digested peptides, modified peptides can be identified by a mass shift
equivalent to the added modification. This measurement will allow identification of the modified
peptides and what modification is present. To determine the location of this modification a
second scan is employed following fragmentation. This MS/MS scan takes place after a specific
(modified) peptide has been selected for isolation. Following isolation, the peptide undergoes
fragmentation such as collision induced dissociation (CID), which will break the peptide bonds.
This fragmentation method results in neutral losses of individual amino acid from the parent
peptide. The resulted peptide fragment masses will be seen in the MS/MS scan showing Cterminal retaining Y ions and N-terminal retaining B-ions. The amino acid which contains the
modification will display a mass shift equal to that of the modification at the respective B or Y ion
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location. This method will allow us to determine the exact location of the modification. Finally,
this peptide can be quantified using the area-under-the-curve created by the intensity of the
peptide signal over the time the signal was present. This quantification method will allow us to
compare relative abundance of modified peptides to non-modified peptides.
Materials and methods
Stable isotope labelling in cell culture
Stable isotope labelling in cell culture (SILAC) was performed as previously described
[94] on HepG2 cells in a preliminary study by a previous member of the lab. In brief, heavy Larginine (R) (13C6, 15N4) and L-lysine (L) (13C6, 15N2) isotopes (Sigma Aldrich) were
supplemented into R&L depleted Dulbecco’s modified eagle medium. HepG2 cells were
cultured in either the heavy labelled medium or normal medium (light labels) to integrate the
labels into the proteome. Following multiple passages heavy labelled cells were treated with 200
mM ethanol for 4-hours. Control samples were treated with PBS. All cells were collected
following the 4-hour treatment. Cells were lysed with 2% SDS and following protein isolation and
quantification samples were mixed at a 1:1 heavy: light protein concentration ratio. Samples
were prepared using the filter-aided sample preparation method followed by desalting on a C18
column and placed under vacuum until dry.
Western blot analysis
Western blot analysis was performed as previously described by Bell-Temin et al. [94].
In brief, proteins were separated by SDS-PAGE and transferred to nitrocellulose. S Ponceau
stain was used to confirm complete transfer. Blocking was performed with 5% dry milk in PBS
containing 0.1% Tween 20. The blot was incubated in the primary antibody overnight at 4° C
with rabbit polyclonal anti-PHPT1 (SC-130229, Santa Cruz). PHPT1 primary antibody binding
was detected by incubation with goat anti-rabbit secondary (1:10000, Cell Signaling
Technology) and activation by picomolar sensitive chemiluminescent reagents (Pierce). Images
were developed on film and quantified using densitometry with Image J. Intensity’s were
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normalized against GAPDH with a rabbit polyclonal anti-GAPDH antibody (1:5000, Cell
Signaling Technology) following stripping and reprobing.
Results and discussion
The initial study with HepG2 cells showed a two-fold increase in PHPT1 oxidation
following acute ethanol exposure compared to the control samples that were untreated. The
western blot analysis revealed that this occurred independent of expression change as PHPT1

abundance was the same after 4-hour ethanol exposure (Figure 5). To verify the ethanolmediated targeted oxidation of PHPT1, we performed modification site mapping using human
recombinant PHPT1 (hPHPT1) to determine if targeted oxidation of PHPT1 was taking place
following ROS exposure. Furthermore, we determined the influence of this modification on the
phosphatase activity of PHPT1 using a novel mass spectrometry-based phosphohistidine
phosphatase assay, a colorimetric phosphatase assay, and explicit solvent molecular dynamic
simulations. The remaining results are contained in previously published work [65] and are
contained in Appendices A and B. This article has been reproduced with the consent of the
publisher (Appendix C).
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Chapter 3: Development and characterization of phosphohistidine phosphatase 1
knockout and overexpression models in Mus musculus.

Summary
Phosphohistidine modification and signaling in mammalian models has not been well
characterized despite its importance in other cell types in mechanisms such as two component
histidine kinase signaling in bacterial models [59]. The presence of a known phosphohistidinespecific phosphatase in mammals, PHPT1, further suggests phosphohistidine plays a crucial
role in cellular functions. In this study, we use two methods to create a PHPT1 overexpression
and knockout model for further understanding phosphohistidine signaling. The overexpression
method employs an adenoviral-based construct for liver-specific overexpression, and the
knockout was achieved using cre recombinant-based gene recombination. Furthermore, these
models were both characterized using high resolution mass spectrometry-based proteomics to
further validate the models and provide insight into the influence of phosphohistidine signaling
manipulation. These models allowed us to identify PHPT1 as embryonically lethal and
determine novel key regulators influenced by its expression. Implementation of these models in
future studies will lead to further insight into the role of phosphohistidine signaling and PHPT1
regulation in mammalian cells.
Introduction
Phosphohistidine phosphatase (PHPT1) was discovered in porcine liver in 2002[41].
PHPT1 shows phosphatase activity toward phosphohistidine residues in vivo and can catalyze
the dephosphorylation of phosphoramidate [43] and phospholysine [44] in vitro. PHPT1 has only
a few known targets include KCa3.1 calcium ion channel [39], ATP-citrate lyase [35], and G30

protein (β subunit) [37]. Given the robustness of phosphohistidine modifications predicted to
occur in mammalian cells it is likely that there are many other targets of PHPT1 yet to be
elucidated [87]. Additionally, the effect of PHPT1 expression on cellular function in vivo has yet
to be fully understood. Studies investigating the effects of PHPT1 knockdown have been
performed in a few different cell types. In pancreatic β cells and neuronal cells, PHPT1 has
been shown to influence important pathways, such as insulin secretion and cell proliferation,
respectively [45, 46]. PHPT1 overexpression has also been performed on cancer cell lines,
showing PHPT1 plays a role in cell migration and possibly epithelial-mesenchymal transition
(EMT) [51, 66]. These studies show that PHPT1 expression has influence on critical cellular
pathways throughout the mammalian system. PHPT1 expression is shown to be most elevated
in heart, spleen, liver, muscle, and brain tissues [41, 95]. PHPT1 is also part of the Janus family
of proteins according to the family domain classification available on the Universal Protein
Resource (uniport.org), which are best characterized in Drosophila melanogaster and involved
in sex differentiation during development [49]. It is the only known phosphohistidine
phosphatase to be a part of this family of proteins.
PHPT1 targets phosphorylated histidine residues for removal of the phosphate group
from the amino acid [41]. Phosphohistidine is also not well characterized. The modification is
best known for its acid labile nature [56], which makes it more difficult to study than the well
characterized phospho- serine, threonine, and tyrosine residues [96]. Phosphohistidine can take
place at the N-1 or N-3 on the imidazole side chain [36]. The N-1 modification is generally less
stable and most often occurs as an intermediate on phosphatase or kinase enzymes during
phosphate group transfer between ATP and the substrate [97]. Histidine residue on these
enzymes are often the catalytic amino acid, which is the case for H53 in PHTP1 [62] as well.
The N-3 modification is associated with long-term phosphorylation and requires a kinase and
phosphatase for addition and removal [87]. Targets of this kind of phosphohistidine modification
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include those of PHPT1 as well as histone H4 (which is shown to be a target of PHPT1 in vitro
but not in vivo) [38, 43].
Despite the lack of knowledge currently on phosphohistidine signaling in mammals, it is
still estimated that 6% of protein phosphorylation occurring are phosphohistidine modifications

[87]. This modification has been shown in well characterized species and mammals to cause
activation/inhibition and influence signaling of molecules. Therefore, PHPT1, a phosphohistidine
specific phosphatase, is likely a key player in many pathways via phosphohistidine regulation.
Canonical pathways regulated by phosphohistidine can be elucidated using PHPT1 expression
manipulation followed by proteomic analysis. Using an in vivo mouse model will provide a model
with high translational potential due to similarity with the human proteome. Furthermore,
characterization of the PHPT1 expression in a large vital organ such as the liver will provide
ease in targeting, large quantity of tissue available per animal, and insight into consequences of
influencing liver regulatory pathways, which are key for the entire organ system function.
Expression manipulation has been achieved in two ways. Overexpression of PHPT1 was
assessed using a tail-vein injection method of adenoviral vectors encoding for PHPT1 and
enhanced green fluorescent protein (eGFP) control viruses with an albumin promoter (for liver
specificity). This method has been previously described in Wilson et al [98]. Adenoviral vectors
were obtained and constructed by Vector Biolabs (Pennsylvania). To create the knockout
model, male and female C57BL/6J PHPT1tm1.1(KOMP)Vlcg heterozygous(het) mice were
created by the KOMP repository at University of California (UC) Davis through cre-mediated
deletion with a LacZ gene substitution. These mice were obtained at 4-6 weeks old and were
cross bred with C57BL/6J wild-type mice to confirm fertility and for colony establishment.
Characterization was performed using discovery-based proteomics, allowing us to take a
snapshot of proteomic changes induced by PHPT1 expression alteration. With this study, we
hope to further understand the role PHPT1 plays in cellular regulation in vivo.
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Materials and methods
Adenovirus animal models
Male C57BL/6J mice were obtained from the Jackson Laboratory and fed a standard
rodent chow and water ad libitum, whilst maintained on a 12h light and dark cycle. Adenoviral
vectors encoding for PHPT1 and eGFP control viruses with an albumin promoter (for liver
specificity) were obtained and constructed by Vector Biolabs (Pennsylvania). Mice were injected
with 1X109 plaque-forming units (pfu) of adenovirus via tail vein at 10-12 weeks of age. Mice
were sacrificed 5 days later for gene expression analysis. All animal studies were performed in
compliance with IACUC approved protocols by the University of South Florida.
Cre recombinant animal models
Male and female C57BL/6J PHPT1tm1.1(KOMP)Vlcg heterozygous mice were created
by the KOMP repository at University of California (UC) Davis through cre-mediated deletion
with a LacZ gene substitution. These mice were obtained at 4-6 weeks old and were cross bred
with C57BL/6J wild-type mice to confirm fertility and for colony establishment. Tail snips were
obtained for genotype verification. Mice were sacrificed at 15 weeks old and multiple tissues
were obtained and immediately snap frozen in liquid nitrogen for preservation to be used for
phenotyping and characterization.
Genotyping
Tail snips were obtained from mice less than 21 days old for DNA extraction. DNA
purification was performed using the GeneJET genomic DNA purification Kit (K0722, Thermo
Scientific) according to the manufacturer’s instructions. PCR primers for both the PHPT1 and
LacZ+ gene were provided by UC Davis, and PCR’s were performed using a PTC-200 thermo
cycler (MJ Research) at UC Davis specified parameters. DNA separation was carried out on a
1% agarose gel in Tris Borate EDTA (TBE) buffer (Thermo Scientific) with 0.1% ethidium
bromide. Visualization was completed using the LICoR AI600 instrument with UV light exposure
of less than 0.5 sec.
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Phenotyping
PHPT1 expression levels were determined using western blot analyses of various tissue
types. Tissues were homogenized in a 125 mM Tris buffer with protease and phosphatase
inhibitors on ice. Protein extraction was performed in a 4% SDS buffer at 95° C followed by
sonication and centrifugation for protein purification. Protein quantification was performed using
the Pierce 660 nm protein assay solution (Thermo Scientific) supplemented with an ionic
detergent compatibility reagent (Thermo Scientific) on a 96 well plate. Three technical replicates
were used for each sample and two for each BSA standard. Western blot analysis was carried
out using TGX any KD gels (Bio-Rad) followed by a semi-dry transfer to either nitrocellulose or
PVDF membranes. Nitrocellulose membranes were Ponceau stained immediately following
transfer for confirmation of equivalent loaded total protein. PHPT1 was probed for using a 1:500
dilution in 5% BSA of the N-23 anti-PHPT1 antibody (SC-130229, Santa Cruz). A 1:5000 dilution
in milk of the HRP conjugated goat anti-rabbit secondary (Cell Signaling Technology) was used.
Development was carried out using SuperSignal chemiluminescent reagent (Thermo Scientific)
and signal intensity was measured on the AI600 (LICoR) instrument. Loading control was
carried out using either a 1:2000 dilution of anti-GAPDH (Cell Signaling Technology), or 1:1000
dilution of anti-β-actin (Cell signaling technology), depending on the tissue type, and a 1:5000
dilution in milk of an HRP conjugated rabbit anti-mouse secondary (Cell Signaling Technology).
Further quantification analysis was performed using an eGFP ELISA kit (Abcam,
ab171581). The procedures were followed according to the manufacturer, in brief, standards
were created in technical duplicates and samples in technical triplicates and PBS was used for
the blank. Wells contained 100 µl of either samples or standard as well as 10 µl of the balance
solution and 50 µl of the conjugate solution. Plate was mixed for 1 hour at 37° C. Following
washing, 50 µl of substrate A and B were added to each well and incubated for another 15 min
at 37°C. The reaction was halted with 50 µl of Stop solution and read on a microplate reader
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(Versa Max, Molecular Devices) at 495 nm. Results were calculated using SoftMax Pro software
(version 5.4.1) based on a 4-parameter logistic standard curve fit.
Mass spectrometry-based phenotypic characterization
Following protein extraction from liver tissues, 150 µg of protein from tissue lysates were
prepared for mass spectrometry analysis using the filter aided sample preparation (FASP)
method previously described [75]. In brief, samples were placed on a 30kDa filter spin column
(Millipore) and washed with 8 M urea to remove any detergents. Buffer exchange was followed
by N-terminal alkylation and reduction using Idoacetamide and DTT respectively. Samples were
then trypsin/Lyc-C digested (Promega) overnight at 37° C and eluted with 50mM Ammonium
bicarbonate and 0.5 M sodium chloride. Samples were then desalted using a Sep-Pak C18
desalt columns (Waters). Following centrifugation under vacuum until dryness, samples were
resuspended in 0.1% formic acid for mass spectrometric analysis.
Generated peptides were separated using a reversed phase PepMap100 C18, 3 µM, 100
Å, 75 µM I.D. X 50 cm nanoviper column (Thermo), with a PepMap100 C18, 3 µM, 100 Å, 75 µM
I.D. X 2 cm cap trap (Thermo), on an Ultimate 3000 (Thermo Fischer) HPLC system over a twohour gradient (5-40% acetonitrile in 0.1% formic acid). Mass spectrometric analysis was
performed by a hybrid quadrupole-Orbitrap instrument (Q-Exactive Plus, Thermo), using a top
10 data-dependent acquisition method with a dynamic exclusion time of 20 seconds. Full scan
and MS/MS resolution was 70,000 and 17,500 respectively. High-resolution MS data were then
searched against the Uniprot mouse proteome database using the MaxQuant (1.6.0.16,
maxquant.org) search algorithm. Variable mods included phosphorylated serine, threonine, and
tyrosine, and methionine oxidation. First search peptide tolerance was 20 ppm and the main
search peptide tolerance was 4.5 ppm. Identifications were accepted at a protein and peptide
false discovery rate of less than 1% and overall localization probabilities of ≥95% for modified
peptides.
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Normalized protein abundances were organized as label free (LFQ) intensities in the
protein groups file generated by MaxQuant. Further LFQ statistical filtering was performed using
Perseus (version 1.6.0.7, http://www.perseus-framework.org/) software to determine significantly
differentially expressed proteins between treatment groups. Significant protein expression fold
changes between groups were uploaded to Ingenuity Pathway Analysis (IPA) (Qiagen) for a
bioinformatic analysis revealing predicted upstream and downstream regulators as well as
activated/inhibited pathways. IPA results were used for phenotypic characterization of PHPT1
overexpression and knockout models and key regulators identified were validated by western
immunoblotting. Liver samples were compared between male PHPT1 and eGFP
overexpression, with male het and wild-type mice of similar ages.
Statistical analysis
Data are presented as means with error bars representative of ± standard error.
Statistical significance was determined by an unpaired, two-tailed, Welch modified T-test.
Microsoft Excel (Office 365, 2012) and Perseus (version 1.6.0.7, http://www.perseusframework.org/) were used to perform statistical analyses of PHPT1 and eGFP overexpression
as well as PHPT1 het and wild-type data. Proteomic dataset filtering utilized a Z-score for each
protein determined statistically significantly by Welch’s t-test for additional filtering of LFQ data.
This method has been used previously to produce highly efficient discriminative analysis of LFQ
data [76].This Z-score for each protein reflects the difference between the fold change of that
protein and the mean fold change of all proteins, relative to the standard deviation of the
population [99]. Proteins with a Welch modified t-test value of <0.05 and a │Z-score│>1 were
deemed significant and uploaded for Ingenuity pathway analysis.
Results and discussion
Validation of adenoviral PHPT1 expression in mouse models
To study the effects of PHPT1 overexpression in vivo in male C57BL/6J mice adenoviral
based injections were used. Adenovirus has been shown to specifically target the liver [98]. In
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addition, an albumin promoter was added to the viral vector to increase liver specificity. This
methodology is advantageous in that it allowed us to specifically target a single organ in adult
mice to prevent any adverse effects of PHPT1 expression on development. Mice injected with
either the PHPT1 or eGFP viral constructs showed liver specific overexpression and no change
in expression in the spleen or other organs. Western blot of PHPT1 expression showed a
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significant increase in PHPT1 expression compared to the eGFP mice, 5 days post injection
(Figure 6a). To further validate this overexpression model and liver specificity eGFP
translational expression was confirmed using an ELISA kit to measure absolute protein
expression. EGFP expressing liver samples showed approximately 2 ng/ml of GFP as
compared to less than 0.1 ng/ml in the PHPT1 liver samples and both spleen samples.
In the knockout model, phenotypic validation of PHPT1 expression was performed on
tissues known to highly express PHPT1 in wild-type mice (liver, spleen, muscle, and brain).
PHPT1 protein expression in the het mice was seen to significantly decrease on average by
approximately 50% in liver, spleen, muscle, and brain tissues as compared to the wild-type
(Figure 6b). This result is concurrent with the genotype data in which the het mice contain only
one of the two alleles for PHPT1 expression. These data suggest that PHPT1 transcription and
translation are reduced organism wide by 50%.
Breeding colony development and validation
Male and female C57BL/6J mice were genetically modified at the KOMP repository with
a PHPT1tm1.1(KOMP)Vlcg method. This method created heterozygous mouse with a nonconditional knock-out lacZ gene. Genotypes of these mice were initially confirmed using tail-snip
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DNA amplification of PHPT1 and the lacZ recombinant gene through a PCR analysis. The wildtype mice displayed expression of only the PHPT1 gene, whereas the heterozygous knockout
(het) showed expression of both the PHPT1 gene and the lacZ reporter gene. These mice were
bred, and offspring were similarly genotyped to determine the viability of a full PHPT1 knockout.
Following multiple het-het crosses (n>20) genotyping revealed no post embryonic complete
PHPT1 knockout mice. This result suggests a full knockout of PHPT1 is dying in-utero. A chisquare test of the total offspring born from these crosses (N=128) allows us to say with >99%
probability (2 degrees of freedom), that the het-het crosses do not follow the expected
Mendelian genetics (Table 1). Possible mechanisms for this lethality were not investigated,
however, many of the pathways that PHPT1 is known to be associated with could be involved in
this mechanism.
Age expression validation of PHPT1
After expression validation of PHPT1 models was complete we determined if the
expression of PHPT1 was dependent on the age of the mouse considering our different model
validations came from varying age ranges. Liver from 11-18 weeks old mice were extracted
from both sexes and compared to each other and the 8-10-week-old mice used for the ethanol
exposure models (Chapter 4). Expression validation was performed using a western blot against
PHPT1 and a β-actin loading control. There was no significant difference between PHPT1
expression regardless of age group or sex. Through these results, we were able to conclude
that age and gender does not influence PHPT1 expression levels.
PHPT1 animal model characterization
Following the creation and validation of our PHPT1 overexpression and knockout
models, we wanted to further characterize the influence of PHPT1 expression and
phosphohistidine signaling on liver function. Global proteome levels where measured using
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high-resolution mass spectrometry from liver extracts from eGFP, PHPT1 overexpression, wildtype, and Het mice. Mass spectrometry intensities were used to further validate PHPT1
expression between samples. Data showed a 13-fold increase in PHPT1 expression compared
to the eGFP mice and a 2-fold increase from the het to the wild-type mice (Figure 6a & b).
These data coincided with our western blot analysis data used for initial validation.
Using high-resolution mass spectrometry proteome expression data, we next
investigated key regulators, pathways, and possible downstream targets influenced by PHPT1
expression changes. These results were elucidated using the core analysis feature in Ingenuity
Pathway analysis, which predicts these factors based on experimentally provided expression
fold-changes. IPA utilizes a z-score algorithm, in which a z-score of greater than 2 or less than 2 represents activation or inhibition, respectively. The p-value of overlap represents the overlap
in targets influenced by the regulator or pathway and those identified experimentally as
significantly changed. A low p-value of overlap represents a key regulator that shares many
targets influenced by our experimental treatment, in this case PHPT1 expression.

Bioinformatic analysis of protein expression fold changes revealed both PHPT1
overexpression and knockout models shared significant overlap of downstream targets with key
regulators HSD17B7, 17β-estradiol, and MYC (Table2). HSD17B7 is involved in steroid and
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cholesterol regulation via 17β-estradiol synthesis and 3-ketosteriod reductase function [100].
MYC and 17β-estradiol are regulators of cell survival [101] and proliferation [102], respectively,
and both well-known players in cancer development [103, 104]. Although, both PHPT1
overexpression and knockout induced expression changes have significant overlap with these
regulators, it appears they are influencing these processes through unrelated mechanisms.
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Furthermore, the proteins influenced by each PHPT1 expression state differ greatly. The
proteins identified as significantly influenced and overlapped with these regulators were unique
to each PHPT1 condition (outer nodes Figure 7a-d). PHPT1 knockout identified the GnRH
analog as the unique regulator to be predicted as significantly influenced by expression changes
(Figure 7e). PHPT1 overexpression did not identify any regulators as significantly influenced (2<z-score>2).
Furthermore, the overlap with the top 3 canonical pathways of each condition do not
coincide (Table 2), and there were no pathways identified with significant overlap in both
conditions. However, the pathways identified in each condition give much insight into possible
mechanisms being influenced by PHPT1 expression. PHPT1 overexpression changes show
overlap with three pathways of degradation. The glycogen and S-methyl-5'-thioadenosine
degradation pathways are often a result in an increase of cell proliferation and transcriptional
activation [105, 106]. In addition, the degradation of α-tocopherol is in response to an increase
in antioxidant production [107] and leads to an increase in β-oxidation via the production of αcarboxyethylhydroxychroman [108]. Alternatively, the heterozygous PHPT1 model has
significant overlap with two pathways that lead to lymphocyte-mediated apoptosis (Table 2).
Specifically, in the Nur77 signaling pathway, apoptosis is activated via Nur77 interaction with
RXRα [109]. In addition, overlap is observed with diabetes type 1 signaling. This kind of
signaling originates from incomplete hormone response between the liver and the kidney[110].
All three of these pathways were identified due to the measured decrease expression of CASP3
and MHC I. MHCI is one of many known upstream indicators of all three pathways, and CASP3
is a common downstream indicator of pathway activation. CASP3 inhibition is also an indicator
of cell survival as its activation is necessary for apoptosis[111]. These pathways of overlap
reflect a PHPT1 overexpression phenotype which is thriving and prepared for an oxidative
stress response, and a heterozygous phenotype that seems to be reacting to an external stress
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already. The only difference between the two cell types is the initial expression levels of PHPT1
and the resulting potential change in phosphohistidine modifications.
Conclusions
The significance of phosphohistidine signaling in mammals is yet to be fully understood.
Despite its likelihood of being highly utilized in key pathways and functions, it remains one of
least understood phosphorylation modifications, especially compared to phospho- serine,
tyrosine, and threonine. Implications of further understanding the role of phosphohistidine
signaling go beyond just understanding cellular mechanisms. Phosphohistidine has been shown
to play roles in various diseases, including many forms of cancers [52, 53, 66, 67, 112] and
pancreatic diseases such as type II diabetes [46]. In this investigation, we created and
characterized much-needed animal models for investigating the role of PHPT1-mediated
phosphohistidine signaling.
Adenoviral-based constructs have previously been shown as effective tools for inducing
liver-specific overexpression of a protein of interest. In our study, we effectively used this to
create a liver-specific PHPT1 overexpression model. This model shows a significant increase in
PHPT1 overexpression that can be maintained for several weeks (see Chapter 4: Expression
Validation). In addition, the creation of the PHPT1 overexpression model requires very little time
and provides an easily reproducible method for inducing PHPT1 overexpression. Our
characterization of this model provides insight into the impact decreased phosphohistidine
levels have on liver homeostasis. In addition, these data provide a reliable control to compare to
treated PHPT1 overexpression models. The ease and specificity of this method gives it the
potential to be utilized for organ-specific siRNA mediated knockdown, in addition to
overexpression. We intend to apply this method for liver-specific PHPT1 knockdown in future
studies.
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However, we did create and characterize a knockout model employing the Cre-mediated
recombinant heterozygous mice provided by the KOMP repository at UC Davis. We validated
the genomic expression and translational expression of PHPT1 in this model across multiple
tissues. We demonstrated that this model is a valid animal-wide PHPT1 heterozygous knockout.
Further characterization of liver tissue from this model was done to create a direct comparison
with our overexpression model. This characterization provides two benefits: we now have a
base model for experimental comparison and we gained insight into the influence of increasing
phosphohistidine signaling on an organism-wide level.
We also determined for the first time that PHPT1 is an embryonic lethal knockout in
C57BL/6J mice through offspring genotyping and Mendelian genetic comparisons. This
discovery adds to the potential importance PHPT1 has in cell regulation and highlights it is a
necessary protein during embryonic development. PHPT1 is part of the Janus family of proteins
which are well characterized in Drosophila melanogaster as proteins involved in sex
differentiation and development. So, it is likely PHPT1 may have similar roles in mammalian
development that have yet to be determined. Furthermore, PHPT1 overexpression has been
shown to be involved in EMT in cancer cells [67]. This study further suggests that PHPT1 and
phosphohistidine are involved in regulating cell differentiation. A complete PHPT1 knockout
could be disturbing the fragile differentiation of cells during development, leading to embryonic
lethality. Further investigation of the mechanisms involved in PHPT1-induced embryonic
lethality are needed.
Most importantly, characterization of these two models reveals PHPT1 expression has a
wide range of influence on cellular functions. It appears that overexpression and knockout of
PHPT1 impacts cellular function through distinct mechanisms that do not coincide. PHPT1
knockout experiments in cell cultures have been shown previously to influence ACL expression
[45], and cell movement [51]. Furthermore, PHPT1 overexpression studies, have been
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correlated to cell viability [45], cell proliferation [66], and insulin regulation [46] via ACL function.
Our study shows a great amount of overlap in expression targets with these mechanisms.
However, we reveal varying signaling pathways induced by PHPT1 overexpression versus the
heterozygous mouse model. Further investigation into how PHPT1 expression is interacting with
the downstream targets is necessary to better understand the significance of phosphohistidine
signaling in the mammalian liver.
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Chapter 4 – The influence of PHPT1 expression on ethanol-induced hepatic steatosis
during chronic ethanol exposure
Summary
Following characterization of both the PHPT1 overexpression and knockout models,
further investigation of the influence of PHPT1 expression on ethanol-induced hepatic steatosis
was investigated. Initial studies of the 10-day chronic plus binge ethanol mouse model
confirmed the model validity. Overexpression of two key ethanol response proteins CYP2E1
and EPHX1 were identified (Figure 8a). In addition to model validation, this initial study
determined PHPT1 expression to be significantly decreased following chronic ethanol exposure

(Figure 8b). Further model validation was reflected by the formation of lipid droplets and
hepatocyte ballooning seen in the ethanol-treated mouse livers but not in the pair-fed control
mice (Figure 9). This discovery led us to further investigate the influence of PHPT1 expression
on the onset of alcoholic liver disease and elucidate possible upstream regulators and canonical
pathways involved in phosphohistidine signaling.
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Both the PHPT1 overexpression and PHPT1 knockout models were administered the
10-day chronic plus binge ethanol exposure model and livers were collected for phenotype
characterization. Samples from each treatment group were analyzed for disease progression
markers such as AST, ALT, triglyceride levels, and blood alcohol concentration. Samples were
also taken for H&E staining to assess the development of steatosis. PHPT1 expression
validation was also performed post treatment. Finally, mass-spectrometry based phenotypic

characterization was done using label free quantitation of liver lysates to determine significantly
differentially expressed proteins following ethanol response and between PHPT1 expression
cohorts. This information was used to determine upstream regulators and canonical pathways
involved in phosphohistidine signaling during chronic ethanol exposure.
Experiments revealed that PHPT1 overexpression mice had a decrease in circulating
triglycerides and a lower development of steatosis, which was assessed via independent
pathology scoring, than the ethanol treated GFP overexpression control group. However, our
PHTP1 heterozygous mice showed additional susceptibility to developing high triglyceride levels
and the onset of steatosis. This result was reflected by similar phenotypes observed between
the heterozygous control groups which were provided a higher-fat controldiet with no ethanol,
and our wild-type ethanol groups. Both groups demonstrated significantly high triglyceride levels
and large amounts of hepatocyte ballooning and lipid droplet accumulation. In addition, the
heterozygous control group showed increased inflammation and necrosis around the vascular
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islets in the liver. This result was also observed in the heterozygous ethanol treated samples,
but not in the wild-type control samples. This information suggests PHPT1 expression correlates
with the onset of liver steatosis, and possibly plays a role in the development of ALD and nonalcoholic fatty-liver disease (NAFLD).
To further understand the mechanism by which PHPT1 is influencing the development of
fatty liver disease, we performed advanced mass-spectrometry based phenotypic
characterization. Proteomics allowed us to take a snapshot of the global proteome following the
control and ethanol treatments and to quantify changes in protein expression between
(patho)physiological states. Furthermore, it also allowed validation of PHPT1 expression and
disease progression. Our analysis found that PHPT1 expression was consistently decreased, in
the range of 20-60%, following ethanol exposure regardless of its initial expression levels.
Furthermore, bioinformatic analysis predicted PHPT1 expression to influence susceptibility of
ethanol-induced hepatic steatosis. This susceptability is predicted to be mediated through
PPARα/ RXRα pathway regulation as well as regulation of cytochrome P450s via ABCB6
signaling and other transcriptional regulators. These pathways are known players in ethanol
metabolism and ROS response [13]; however, they have not previously been shown to be
involved in phosphohistidine signaling. Although further validation of these targets is necessary
to fully understand the mechanism of PHPT1 and phosphohistidine signaling in these pathways,
it is clearly apparent that PHPT1 expression is playing a novel role in liver injury susceptibility.
Introduction
Ethanol-induced hepatic steatosis
The progression and severity of ALD has been widely discussed previously
(Introduction: Alcoholic liver disease). As mentioned previously, the progression of this disease
begins with the onset of fatty liver or more specifically ethanol-induced hepatic steatosis. The
development of this phenotype is characterized primarily by the histological changes that take
place in hepatocytes. These changes are induced by overactivation of ethanol metabolism
48

pathways and result in dramatic changes in lipid homeostasis and cell signaling [11].
Hepatocytes perform the primary role of the liver to remove toxins from the blood stream. Given
this, hepatocytes are well suited with a plethora of metabolites and anti-oxidant proteins to
compete against moderate ethanol exposure [113]. However, chronic ethanol exposure will
interfere with normal ethanol metabolism. This interference occurs in multiple ways, including
ROS oxidation, changing in the acetyl-CoA pool, and disruption of fatty acid oxidation [11]. The
metabolism alterations directly create visual changes in hepatocyte histology. Development of
hepatocyte ballooning and Mallory bodies occurs as a result of the increase in fatty acid
production and decrease in fatty acid β-oxidation [13]. In addition, hepatocyte stress leads to
recruitment of the resident liver immune cells, Kupffer cells, which release inflammation causing
cytokines and interferons [19]. This change results in further liver damage. Often this damage is
initially present exclusively surrounding the portal veins where blood first interacts with the liver.
However, as these cells become deactivated due to over exposure, this phenotype spreads to
the rest of the liver. This damage combined with efforts to replace and repair damaged cells
leads to liver swelling, which is often the earliest identified symptom of ALD [13]. However, at
this point, fibrosis is occurring, and the development of early stage hepatitis is occurring. At this
stage, the potential for minimally invasive full recovery is significantly lower than during initial
hepatosteatosis [2]. Unfortunately, without a biopsy, hepatosteatosis is generally asymptomatic.
Further understanding in how this disease develops and finding novel mechanisms influenced
by chronic ethanol exposure will aid in early identification and prevention.
Mouse models of ethanol feeding
The mouse model has been an exemplary one used to study the onset, progression, and
impact of ALD for many years. During this time, many models of exposure have been developed
for understanding different facets of disease progression [78]. These exposure models vary by
focus of study in the progression of ALD. Models which are developed to look simply at animal
49

behavior or habituation often give the mouse a choice between ethanol consumption and not
[114]. Models looking for short-term exposure or studying the immediate impact of ethanol on
the organism will often employ a gavage ranging from 10-1 g ethanol/kg bodyweight depending
on the desired severity of the binge. This range gives blood ethanol concentrations (BEC) from
0.5 g/dl to 0.05 g/dl, respectively. Another binge model that has been recently developed uses
ethanolinfused gelatin to encourage quick but less forceful consumption [115]. Furthermore,
there are many models which investigate the impact of long term or chronic ethanol exposure.
These models range from a multichoice consumption [116], to a purely ethanol supplemented
diet [77], and even a normal chow but using ethanol vapor to provide consistent ethanol
exposure [117]. These models usually aim at inducing reproducible severity of alcoholic liver
disease while at the same time having a relevant control that is exposed to the same
environmental factors but not ethanol. This accomplishment can be challenging considering the
caloric burden and stress ethanol consumption has on an organism.
The model we choose to use is the 10-day chronic plus binge ethanol model, which
consists of a liquid 5% ethanol diet for 10 days and is concluded with a 5 g ethanol/kg body
weight gavage [77]. The control groups from this model also receive a liquid diet which contains
the same calorie contents and are given a gavage supplemented with maltose dextrin equal in
calories/volume to that of the ethanol diet. This model is well characterized in creating moderate
to severe liver steatosis (Figure 8). This phenotype is validated by H&E stained liver sections
developing motifs such as hepatocyte ballooning, lipid droplet, and Mallory body formation
(Figure 9) [77]. In addition, liver injury is characterized further by showing an increase in the
amounts of circulating ALT, AST, and triglyceride levels as compared to the pair-fed controls. In
human models, the ratio of AST/ALT levels have been shown to indicate severity of ethanolinduced liver injury [118]. However, in the mouse model, significant upregulation of either of
these metabolites are considered a marker of ALD [77]. We have also verified that known
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ethanol-induced expression changes are taking place on proteins such as CYP2E1 and EPHX1
(Figure 8a), which are both known to be upregulated following chronic ethanol exposure [24]. It
was also found the PHPT1 expression levels are down regulated following the exposure model
as well (Figure 8b). This led us to investigate further how expression of PHPT1 is influencing the
onset of this liver injury.
Materials and Methods
10-Day chronic plus binge ethanol diet
PHPT1 expression altered, eGFP induced, and wild-type C57BL/6 mice were split into
cohorts for ethanol or control diet treatments. Male and female mice were used for the
heterozygous and wild-type cohorts and only male mice were used for the PHPT1 and eGFP
overexpression models. Each cohort initially consisted of 3-10 mice per treatment type. This
model was based on the publication of Bertola et al [77] using the Lieber DeCarli liquid diet
formula. In brief, ethanol-treated mice received a liquid diet that was 5% vol/vol ethanol as their
only source of nourishment. Control mice received a liquid diet as well that did not contain
ethanol but was equivalent in calories per serving. Consumption of this diet was monitored for
both groups over 10-days to ensure consistent intake occured between pair-fed groups.
Following the 10th day of consumption, ethanol treated mice received a 5 g/kg ethanol/body
weight gavage with a 31.5% vol/vol ethanol solution. Control mice receive a gavage consisting
of 9g/kg maltose dextrin/body weight with a 45% wt/vol solution. Mice were then sacrificed
9hours later and their blood alcohol concentration, AST, ALT, and triglyceride levels were tested
to determine disease severity.
Fluorescence microscopy
Florescence microscopy was carried out on formaldehyde-fixed tissue sample slides
prepared by the Moffitt Tissue core. Samples that were not stained were provided and used to
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determine eGFP expression via fluorescent excitation. Slides were first treated with a DAPI
nuclear counterstain solution (Pierce) to stain the nuclear envelope. This was most effective on
single cells near the edge of the formaldehyde-fixation area. Slides were viewed using an
UtlraVIEW ERS spinning disk confocal microscope (Perkin Elmer) with a solid-state laser
emission at 405nm and image capturing was performed using the Velocity software set to the
same parameters for all samples. This instrumentation was provided generously by the CMMB
core facilities.
Western blotting
Lysates were derived from control and ethanol diet-treated mouse livers and were
analyzed by western blot to verify PHPT1 expression levels. Western blot analysis was carried
out using TGX any KD gels (Bio-Rad) followed by a semi-dry transfer to either nitrocellulose or
PVDF membranes. Nitrocellulose membranes were ponceau stained immediately following
transfer for confirmation of equivalent loaded total protein. PHPT1 was probed for using a 1:500
dilution in 5% BSA of the N-23 anti-PHPT1 antibody (SC-130229, Santa Cruz). A 1:5000 dilution
in milk of the HRP conjugated goat anti-rabbit secondary (Cell signaling technology) was used.
Development was carried out using SuperSignal chemiluminescent reagent (Thermo scientific)
and signal intensity was measured on the AI600 (LICoR) instrument.
Histology
Immediately following sacrifice, liver tissue sections were taken for paraffin-embedding
and hematoxylin and eosin staining. Tissue sections were taken from the center of a large lobe
of liver tissue and from pair-fed animals in each treatment group. Paraffin-embedding,
formaldehyde-fixation and H & E staining was performed at the Moffitt Cancer Center Tissue
Core Histology services. Tissues were then analyzed to identify histological motifs of hepatic
steatosis including the development of lipid droplets, Mallory bodies, hepatocyte ballooning, and
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inflammation. Steatosis scoring was performed on tissues when available based on the
presence of these factors. Samples were formaldehyde-fixed to slides and analyzed under 40X
magnification using a DM2000 upright fluorescent microscope (Leica) with the SPOT camera
and SPOT basic software (Spot imaging) and keeping settings consistent between samples.
Clinical chemistry
Animal serum was removed immediately where approximately 200 ul of whole blood was
acquired from each animal and aliquoted for determining metabolite concentrations. Serum was
tested for ALT, AST, and circulating triglyceride levels by either assay kits (Point Scientific Inc.)
according to the manufacturer’s instructions on a PowerWave XS (BioTek) microplate reader
shortly after extraction, or it was sent to the Moffitt College of Medicine Vivarium, which used an
IDEXX Vettest chemistry analyzer. Metabolite levels where compared between treatment types
and sexes to determine relationship of disease state and fold change in metabolite levels.
Blood ethanol concentration
Blood ethanol concentration of each mouse was also quantified using blood serum
samples. This method was performed using the BEC kit (Sigma-Aldrich). In brief, serum was
spun from the blood samples and 5 µl was diluted at 1:10 for the quantification. BEC standards
were analyzed in duplicate and both a negative and positive control was included in triplicate.
Each sample was tested in triplicate after adding the activating enzyme and sample absorbance
was read on a PowerWave XS (BioTek) microplate reader. Sample concentration varied from
0.005-0.5 g/dl. This concentration translates directly to BEC levels with anything less than 0.08
g/dl considered insignificant and greater than 0.08 g/dl consistent with the binge ethanol
consumption model. BEC levels were tested for all mice in which enough serum was able to be
extracted.
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Label free quantitation of ethanol treated mouse liver samples
Mouse liver samples were obtained from each cohort immediately following the
conclusion of ethanol treatment and sacrifice. Livers were preserved by cryo freezing and 35-40
µg biopsies were used for protein extraction. Following homogenization, lysis took place using a
4% SDS, 100 mM DTT, 100 mM Tris-HCl, pH 7.4 at 95° C for 5 minutes. Total protein was
quantified using the Pierce 660 assay method supplemented with an ionic detergent
compatibility reagent (IDCR) (Pierce). Equal amount of protein was taken from each sample
(150 µg) for detergent removal using the FASP method [75]. In brief, samples were washed
three times with 8 M Urea on a 30 kDa filtered column (Corning). Proteins were then alkylated
using 100 mM iodoacetamide and another buffer exchange was performed to prepare for
Trypsin digestion in 50 mM ammonium bicarbonate. Mass spec grade Trypsin/Lys-C was added
at a 1:50 ratio to protein for digestion overnight at 37° C. Peptides were then extracted for desalt
on Sep-Pak C18 columns on a Supelco Vacuum manifold. Finally, peptides were dried and
resuspended in MS-grade 0.1% formic acid.
Samples were analyzed on a Q-Exactive plus (Thermo Fischer) in-line with an Ultimate
3000 HPLC (Thermo Fischer). Separation was performed on a 75µm X 50cm reversed phase
analytical column, packed with Pepmap100, 3 µm, 100 Å C18. This analytical column was
followed by a 75 µm X 2 cm cap trap packed with Pepmap100, 3 µm, 100 Å C18. Samples were
run on a 120 min gradient from 2% to 50% B (0.1% formic acid in acetonitrile). Full MS survey
scans were performed with a maximum resolving power of 70,000 and 17,500 for MS/MS
resolution. Data dependent analysis was performed selecting the top 10 most abundant
peptides for MS/MS CID fragmentation analyses with a dynamic exclusion time of 20 seconds.
Sample from the same experiment were analyzed concurrently with blanks and quality controls
included throughout the sequence.
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High-resolution raw MS data files were searched against the Mus musculus Uniprot
database using MaxQuant (1.6.0.16, maxquant.org) search algorithm. Label free quantification
parameters were selected for data normalization in MaxQuant to ensure consistency between
samples. Search parameters also included a first search peptide tolerance of 20 ppm and a
main search peptide tolerance of 4.5 ppm with a false discovery rate of less than 1% and overall
localization probabilities of ≥95% for modified peptides. The resulting normalized protein
abundances were used for statistical analysis.
Statistical filtering began with removal of any protein that was not observed in at least
two thirds of a single treatment group. All intensities were then log2 transformed for statistical
analysis. Perseus software (1.6.0.7, http://www.perseus-framework.org/) was used to determine
imputation values, for samples without intensity values, that did not influence the expression
distribution of the data. A Welch’s t-test was performed between treatment types with a
significance threshold of a p-value <0.05. In addition, a Z-score was calculated to determine the
significance of the Welch’s t-test difference between samples and provide further statistical
stringency [76]. Analysis between treatment groups was performed by utilizing a ratio of ratios
between treatments and models. To fully elucidate the influence of PHPT1 expression on
development of ethanol-induced hepatic steatosis, alike variables between groups had to be
offset. This analysis was completed by determining the fold change differences between the
control and ethanol groups of the wild-type models and PHPT1 expression-influenced models
individually. These ratios were then compared to each other to determine factors that were only
affected by the amplified or reduced expression of PHPT1, following ethanol exposure.
To determine possible mechanisms involved in phosphohistidine signaling that are
affecting the development of ethanol-induced hepatic steatosis, we uploaded the significantly
influenced fold-changes to IPA for a core analysis. This program uses our identified fold-change
expression differences to predict regulators, canonical pathways, and disease states being
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activated/inhibited, based on their known relationships. This kind of analysis is known as a core
analysis and searches the database for all known protein interactions. Analytical data provides a
p-value of overlap and z-score of activation for significance. The p-value of overlap represents
the likely hood of overlap in targets identified from the data and a regulator or function known to
interact with those targets in the IPA database. The z-score represents the likelihood of
activation or inhibition of the predicted pathway based on its interactions with the uploaded data.
To further understand the mechanisms involved in phosphohistidine signaling following ethanol
treatment core analysis of the significantly differentially expressed proteins were performed.
Then comparisons between PHPT1 expression models was performed by either taking a ratio of
ratios or by comparing the core analyses of the two models directly to each other, using the
comparison analysis feature, to differentiate regulators and pathways uniquely influenced from
those activated independently of PHPT1 expression. This program provided bioinformatic
insight for determining pathways being influenced by PHPT1 expression that have yet to be
identified. Using IPA to determine potential targets is an especially invaluable tool in the case of
phosphohistidine signaling. Unfortunately, more conventional ways of targeted identification are
far more difficult in the case of phosphohistidine signaling due to its extremely labile nature.
Results and Discussion
Expression validation
For the Ad-PHPT1 and Ad-GFP mouse model’s initial validation that liver-specific
expression remained following the 10-day chronic ethanol exposure was performed. This
validation was done using ELISA and microscopy data to assess eGFP expression and western
blot data to quantify PHPT1 expression. Additionally, mass-spectrometry data was also used to
verify increase expression of both proteins when performing the global proteomic investigation.
EGFP expression was shown to remain constant between the control and ethanol-treated
samples and showed no significant expression in the Ad-PHPT1 samples (Figure 10a).
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Furthermore, fluorescence microscopy was used to visualize the eGFP expression in the AdGFP livers. This method was also performed on Ad-GFP spleen tissue and Ad-PHPT1 liver
tissue as negative controls. Only the Ad-GFP liver tissue displayed green fluorescence
indicative of eGFP expression (Figure 10b-d).

All mice fed ethanol-containing diet were validated for PHPT1 expression following
treatment. PHPT1 overexpression samples were compared directly to the eGFP overexpression
counterpart and heterozygous samples were compared directly to the wild-type mice. PHPT1
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expression levels were initially shown to increase 3-fold between the Ad-PHPT1 overexpression
and Ad-GFP models, and we began with a 2-fold decrease between the wild-type and
heterozygous model (Chapter 3: Figure 6). Ad-PHPT1 and Ad-GFP samples were analyzed
using western blot analysis after ethanol or control diet exposure (Figure 10e). This result
revealed a consistent overexpression of PHPT1 as compared to the eGFP, following exposure
of both the ethanol and control diets. This result was consistent with our mass spectrometry
LFQ data (Figure 10c). PHPT1 expression levels were significantly greater than that of the
eGFP throughout all experimental factors. We did not, however, observe significant decrease in
PHPT1 expression between the ethanol and control mice in either the Ad-GFP or Ad-PHPT1
groups. In addition, the decrease of PHPT1 expression in the wild-type group following ethanol
treatment still remained higher than the PHPT1 expression of the control heterozygous mice
(Figure 10d and f). This result means that these mice began with PHPT1 levels below that of
normal ethanol downregulation. In addition, there was a consistent decrease in PHPT1
expression between control and ethanol-fed mice in the western blot data (Figure 10f). A
significant ethanol-induced decrease in PHPT1 expression was observed in both the wild-type
and heterozygous groups (Figure 10f).
Disease state
Tissues from each treatment and expression group were analyzed for disease
progression in using various techniques. Samples from each group were tested for ALT, AST,
and circulating triglyceride levels in the blood using clinical chemistry. In addition, blood ethanol
concentrations were determined for each mouse, provided a sufficient amount of blood was
available, to verify effectiveness of the gavage. Pair-fed mice had liver tissue biopsies removed
to be paraffin-embed and H&E stain to determine steatosis scores and immunohistochemical
analyses. Mass spectrometry data were also used to verify increased expression of the known
alcohol-induced liver injury markers, CYP2E1 and EPHX1.
BECs from the mice were between 0.005-0.040 g/dl for the control mice and 0.14-0.20
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g/dl for the ethanol-treated mice. This result shows a significant increase in BEC levels following
treatment, as expected. Furthermore, AST and ALT levels were expected to be elevated in the
ethanol-treated mice as compared to the control-fed mice. This result was observed for both
ALT and AST in the Ad-GFP mice and the female wild-type mice as seen in Figure 11a & b.
However, no significant changes were observed between treatments for any other samples. The
measurements for the Ad-GFP and Ad-PHPT1 samples were taken using different methods and
instruments than the heterozygous and the wild-type samples. This inconsistency in methods

could potentially alter the average quantity of the measurements taken, considering the
sensitivity of the two separate methods used varied. Triglyceride (TAG) levels were also
investigated using various methods (described in Chapter 4: methods). Circulating TAG levels
were expected to increase following chronic ethanol exposure and as a result of liver injury
development. A significant increase in TAG following ethanol treatment was observed in all
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samples except for the female heterozygous serum (Figure 11c & d). In addition, TAG levels
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were significantly lower in the Ad-PHPT1 ethanol treated sample that in the Ad-GFP sample.
This suggests PHPT1 overexpression is decreasing the amount of TAG levels produce in
response to ethanol. The opposite of this was observed in our female heterozygous model
where measured TAG levels were pre-elevated in the control sample and remain that way
through the ethanol treatment.
Additional disease phenotyping was performed immunohistochemically using H & Estained paraffin-embed livers from pair-fed mice. Ad-GFP and Ad-PHPT1 livers were scored
based on steatosis development using a scale of 0- normal, 1- mild, 2- moderate, and 3-severe.
Three liver samples were scored from each treatment and the average score was determined
and shown in Figure 11c. As expected, the Ad-GFP control sample showed a mild score and
ethanol treatment induced a severe steatosis score for the treated samples. The control AdPHPT1 samples, however, were scored as normal while steatosis development following
ethanol treatment was only mild. This scoring is reiterated in the histology of the Ad-PHPT1 and
Ad-GFP samples as seen in Figure 11a & b. Both the Ad-PHPT1 and Ad-GFP samples show
very few (if any) hepatocyte ballooning and lipid droplet formations, which are common
hallmarks of steatosis (Figure 12a) [77]. Ethanol-treated Ad-GFP mice show extensive
hepatocyte ballooning, and lipid droplets in approximately 60% of the hepatocytes, which is
indicative of hepatosteatosis. In the ethanol-treated Ad-PHPT1 mice, however, very little to no
hepatocyte ballooning is observed and lipid droplets appear in less than 30% of the hepatocytes
(Figure 12). This histological pattern suggests PHPT1 overexpression is playing a protective
role in the development of fatty liver. PHPT1 heterozygous and wild-type samples were not able
to be officially scored for steatosis. However, in-house histological analysis of the H & E stained
samples was performed to assess the severity of liver injury (Figure 12). The wild-type control
and ethanol-treated mice show similar results to that of the Ad-GFP samples, which is expected.
This result is reflected by a development of lipid droplets in approximately 40% of the
hepatocytes in the ethanol-treated group and none in the control. However, in the heterozygous
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mice, we observed lipid droplet formation and inflammation in both the ethanol-treated and
control groups (Figure 12, black and yellow arrows). Lipid droplet formation is consistently 3040% confluent in both the heterozygous and wild-type ethanol-treated groups. However,
inflammation in the heterozygous control and ethanol samples appears more severe compared
to the wild-type groups (Figure 12, yellow arrows). This difference was seen consistently
throughout histological tissue assessments. Development of inflammation and steatosis during
the control treatment suggests an increase susceptibility to hepatic steatosis induced by
decreased expression of PHPT1.
Phenotypic characterization
To further understand the mechanisms involved in the role of phosphohistidine signaling
and PHPT1 during chronic ethanol exposure, we used mass spectrometry-based proteomics to
characterize the phenotypes induced by each treatment type in each model. This analysis was
accomplished by determining significantly differentially expressed proteins between the control
and ethanol treatment in each model. Then a full core analysis was performed in IPA to
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determine regulators, canonical pathways, and diseases related to the proteins identified as
significantly changed. Finally, the attributes identified were directly compared to each other
using a comparison analysis to determine trends between all three expression levels,
overexpression, wild-type, and heterozygous. Using this method, we identified potential
mechanisms and regulators of phosphohistidine regulation for further investigation.
The top pathways, diseases, and regulators identified are displayed in table 3. These are
accompanied by the calculated z-scores for each, which signify the level of activation/inhibition
that is predicted to occur. A z-score of greater 2 or less than -2 is indicative of significant
activation of inhibition, respectively. Pathways are listed by largest change between
heterozygous and overexpression z-score. The largest of these changes in the canonical
pathways is the PPARα/RXRα activation. This pathway is predicted to be significantly inhibited
in the heterozygous model and not in the overexpression group. This pathway is involved in lipid
homeostasis and specifically in regulating β-oxidation of lipids for exportation [119]. A decrease
in this pathway would result in greater susceptibility to steatosis. In addition, PHPT1
downregulation was predicted to activate multiple signaling pathways, all of which are related to
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G-protein mediated signaling. This activation may be related to the regulation of G-protein
activation by phosphohistidine. Also, NRF2-mediated oxidative stress response is active in both
the over expression and heterozygous conditions. This pathway would be expected to be
activated following ethanol exposure [120].
The top upstream regulator identified is ABCB6 and is predicted to be activated in the
overexpression and wild-type group but inhibited in the PHPT1 heterozygous model (Table 3).
This molecule is an ATPase binding cassette that plays a crucial role in heme synthesis and
porphyrin transport [121]. Protein expression changes identified can be seen in the outer nodes
of Figure 13a and b, which was used to determine predicted activation/inhibition of ABCB6. In
both treatment types, the predominate enzymes involved in this prediction are cytochrome
P450s that were downregulated in the heterozygous model and upregulated in the
overexpression model. Cytochrome P450 regulation, in addition to steroid metabolism, are
additional functions of ABCB6 [122]. The heterozygous model is predicted to activate MYC
which is a well characterized oncogene involved in cell cycle regulation and angiogenesis
(Table 3) [104]. MYC activation can lead to dysregulation of the cell cycle and often results in
cell death via apoptosis [123]. PHPT1 overexpression is predicted to activate NR1I3 and
ethanol as well. Both regulators are expected to be activated following ethanol response, as
NR1I3 is a nuclear receptor involved in xenobiotic regulation [124]. In addition, NR1I3 is
involved in RXRβ and alcohol dehydrogenase 3 regulation [124]. These regulators are not
predicted to be activated in the heterozygous model.
Conclusion
No change in PHPT1 expression levels between the control and ethanol groups in the
Ad-GFP and Ad-PHPT1 samples was unexpectedly observed. This observation, however, could
be due to the limitation of sensitivity whilst analyzing expression levels with such a high dynamic
range between them. In a side-by-side western blot analysis, the high intensity of PHPT1 in the
Ad-PHPT1 samples, over-saturate the blot, making the wild-type PHPT1 levels difficult for
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accurate detection. This same limitation in sensitivity was observed in the mass spectrometry
samples in which PHPT1 intensity levels are upwards of 100-fold higher than the Ad-GFP
samples. This dynamic range makes accurate quantification of PHPT1 in either sample difficult.
Efforts to use a method with a much higher dynamic range were taken, however, were also
either unsuccessful or not able to be completed. A PHPT1 ELISA kit was attempted but did not
perform up to company standards based on its own internal controls and standards. The
availability of additional PHPT1 ELISA kits is scarce due to the limitation of study that has been
performed on this protein. In addition, absolute quantification could be accomplished using
targeted mass spectrometry via either a triple-quadrupole instrument using single/multiple
reaction monitoring or using the Q-Exactive parallel reaction monitoring (PRM) feature.
Contrary, the heterozygous samples showed only 50% less in PHPT1 expression than the wildtype. This expression difference made the dynamic range for quantification much more
attainable via western blot where total protein quantities could be increased to adjust for low
protein concentrations. This adjustment allowed us to observe the expected significant decrease
between treatments as shown in Figure 10f. With PHPT1 expression already low compared to
many other natural liver proteins, PHPT1 expression was still difficult to quantify accurately
using unfractionated total lysate samples with LC-MS/MS analysis using a 2-hour gradient inline with an Orbitrap mass spectrometer. Utilizing a targeted method for PHPT1 quantification
on a triple quad or using the PRM feature on the Q Exactive could have allowed for more
accurate PHPT1 expression assessment [125, 126].
Nonetheless, PHPT1 expression ratios between models were consistent throughout
treatments. This result provided us three consistent expression profiles for characterizing the
role of PHPT1 during chronic ethanol exposure. Additional challenges included, disease
prognosis where consistency among ALT, AST, and histology scoring was not obtained. These
challenges were not without attempted solutions either. The ALT and AST scores were originally
performed according to the NIAAA chronic plus binge model guidelines. The assay kits used
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were the ones recommended by the guidelines [77], however, their success rate, even with their
own standards, were low. Accordingly, we used a core facility with a high specificity instrument
to obtain measurement the second time. Unfortunately, inconsistencies were observed for these
samples as well due to the limitations in whole blood quantities obtained from the animals.
However, these tests did provide us insight on changes in circulating TAG levels. This change is
significant given the proteomic information found relating heavily to lipid homeostasis.
Furthermore, professional steatosis scoring was only performed on the overexpression groups.
This variation was due to that service no longer being available by the time the heterozygous
treatment was performed. Therefore, scoring and histology assessment of these samples had to
be performed in house. Although, not official, the assessments of histological markers of
steatosis development were able to be identified based on numerous publications documenting
hepatic steatosis injuries.
Even with the multiple challenges pertaining to disease phenotyping, we were able to
conclude confidently that PHPT1 overexpression led to a milder disease progression than the
wild-type, and heterozygous expression levels made the organism more susceptible to steatosis
onset even without ethanol treatment. This result makes understanding the mechanisms behind
the role of PHPT1 during chronic ethanol exposure even more vital. Using global proteomic data
to determine significantly differentiated proteins between disease states allows us to determine
possible pathways being influenced by PHPT1 expression. Making sense out of the colossal
amount of data provided by mass spectrometry data is immensely easier to do using a software
program such as IPA. This analysis gives investigators specific pathways and mechanisms to
focus on to determined precisely what PHPT1 functions is influencing.
Our IPA data revealed multiple potential mechanisms of PHPT1 response to ethanol.
Canonical pathways of significance include the PPARα/RXRα inhibition following ethanol
treatment in the heterozygous model. The mechanism of this type of inhibition is unknown but
the phenotype coincides with our other disease phenotype data. Inhibition of the PPARα/RXRα
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would lead to a decrease in fatty acid β-oxidation resulting in lipid accumulation [32]. This
mechanism is known to occur during chronic ethanol exposure [127], however, this is occurring
in the heterozygous model independent of ethanol exposure (Figure 12). Significant inhibition of
this pathway was only seen in the model with decreased PHPT1 expression. In addition, the
heterozygous model showed activation of multiple pathways dependent on G-protein activation.
PHPT1 has been shown to play a regulatory role in G-protein activation through the β-subunit
phosphohistidine phosphorylation [37]. G-protein activation is involved in many cellular
pathways and it is interesting that only these three would be influenced by a decrease in PHPT1
expression. Dysregulation of these specific pathways is known to be involved in abnormal cell
cycle regulation (Rac [128] and CXCR4 [129]) and inflammation (Integrin [130]). Overactivation
of these pathways is only seen in the heterozygous model. This overactivation again, coincides
with inflammation and abnormalities seen in both our control and ethanol-treated heterozygous
groups (Figure 12). These results are further supported by the predicted activation of MYC in
the heterozygous model. MYC is a well characterized oncogene involved in cell cycle regulation,
that often leads to cell death if dysregulated [123]. Hepatocyte cell death would induce an
immune cell response and, if not impeded, would result in an inflammatory response [131].
The only mechanism that is predicted to be significantly activated during overexpression
and inhibited in the heterozygous model is ABCB6 (Table 3). This result is interesting because
ABCB6 functions as an ATP-binding cassette and has no known affiliations with
phosphohistidine or ALD, however, it is known to be involved in other liver diseases [120].
ABCB6 inhibition has been known to negatively affect human health in a variety of diseases
[132]. Other ATP-binding cassettes have also been shown to be involved in ROS removal and
protection [122]. These studies would support the predicted results that ABCB6 inhibition is
creating a more susceptible phenotype and activation would assist in a protective role against
chronic ethanol exposure. Contrary to this finding, however, ABCB6 overexpression has also
been seen consistently in hepatocellular carcinomas and is believed to be a result of disease
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progression from steatosis to carcinoma [132]. In addition, ABCB6 has not been directly
associated with chronic ethanol exposure or ethanol-induced hepatic steatosis previously. This
association would make this mechanism a novel and impactful one to further investigate based
on its predicted functions in chronic ethanol exposure response through phosphohistidine
signaling.
These studies have provided a newfound insight on the significance of phosphohistidine
signaling and PHPT1 in the onset of a universally contracted disease. Phosphohistidine
modifications are potentially influencing previously known and unique mechanisms involved in
the development of ALD. Our study has provided clear evidence that increased PHPT1
expression levels correlate with a milder response to chronic ethanol exposure, and decreased
expression correlates with a higher susceptibility to steatosis and inflammation. In addition, we
have identified numerous potential pathways through stringent statistical filtering and
bioinformatic analysis that could be leading to this correlation. It is evident that there is much
more to know about the role of phosphohistidine signaling in alcohol-induced liver injury and
potentially other mechanisms of disease pathogenesis.
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Chapter 5 – Conclusions and Future Directions
Conclusions
Overview
The initial development of ALD from a healthy liver to the onset of sometimes irreversible
hepatoseatosis is poorly understood. There are many proposed mechanisms involved, including
dysregulation of CYP2E1 [90] in the ethanol metabolism pathway, as well as increase in
inflammatory [17] mechanisms through the JAK/STAT pathway, and loss of lipid homeostasis
via PPAR (α and γ) [127]. However, more detail is needed about this mechanism to understand
how these different pathways are affected by ethanol. This information is vital because early
detection and treatment of ALD is critical in preventing development of more serious forms,
such as cirrhosis, hepatitis, and eventually liver failure. Currently, hepatosteatosis is virtually
asymptomatic and can only be diagnosed following a liver biopsy [11]. This obstacle leads to
most cases of ALD being diagnosed either post-mortem or beyond the point of recovery. A
deeper investigation into the mechanistic details of disease onset is necessary to better detect
the early development of this disease.
Initial studies that were performed identified a potential novel player in ethanol
metabolism. PHPT1 was identified as a target of ethanol-induced oxidation in an acute
exposure model and identified to be downregulated in the chronic mouse model. Furthermore,
the significance of PHPT1 phosphatase activity was poorly understood but it shared an
overlapping target with ethanol metabolism, ATP-citrate lyase (ACL) [35]. PHPT1 is known to
regulate ACL function [45] and ACL is a key regulator of the acetyl-CoA pool that is often
dysregulated by increased ethanol metabolism [133]. There are believed to be many additional
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targets of phosphohistidine phosphorylation that have yet to discovered as well [56]. This theory
makes PHPT1 a probable novel regulator in the onset of ethanol-induced hepatosteatosis.
To investigate the significance of PHPT1, we initially focused on the oxidation
modification induced by acute ethanol treatment. Our studies showed that although PHPT1
oxidation increased by 2-fold, there was no change in PHPT1 expression following acute
exposure. This result led us to characterize the location and extent of oxidation on PHPT1 and
to determine the modification’s impact on phosphatase function. These studies were carried out
using human recombinant PHPT1, and by developing a mass spectrometry-based
phosphohistidine phosphatase assay. This investigation led us to discover that although PHPT1
was being selectively oxidized at Met95, which is a vital residue in substrate binding, it is not
influencing PHPT1 phosphatase activity. Next, we further investigated the role PHPT1
expression was playing during chronic ethanol exposure models.
To understand the role of PHPT1 in ethanol induced hepatosteatosis, we used a mouse
model to provide more biologically relevant information than cell cultures or recombinant
proteins. This mouse model was treated for 10-days with the Lieber DeCarli diet composed of
5% ethanol mixed in with mouse chow in a liquid diet form. The control mice were also given a
liquid diet, but it was supplemented with dextrose instead of ethanol to maintain caloric
consistency between the two groups. Protocols were followed according to the NIAAA 10-day
chronic ethanol plus binge model [77]. C57BL/6J mice were provided only the liquid diet for
consumption over the course of 10 days. The level of consumption from each mouse was
recorded and tracked daily. At the end of the 10-day period, the mice were given a gavage of
5g/kg (ethanol/body weight) 9 hours prior to sacrificing. Control mice were administered maltose
dextrin (9 g/kg in water) instead of ethanol. Mouse livers were removed and used for
determining the extent of ethanol induced liver damage using histology, steatosis scoring, and
proteomics. Blood ethanol concentration (BEC) and clinical chemistry measuring AST, ALT, and
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TAG levels were also assessed based on the blood samples. This method was used for all the
chronic ethanol studies with varying strains of mice.
The initial study, which used the same wild-type male mice for the control and ethanol
treated group, was performed to create a baseline and determine the significance of PHPT1 in
wild-type mice. The BEC levels for the ethanol-treated mice were significantly higher than the
control. The clinical chemistry performed showed a greater increase in AST, ALT, and TAG
levels in the ethanol treated mice as well. Histology steatosis scoring reflected moderate to
severe steatosis in ethanol treated mice samples, in comparison with mild to moderate in the
control samples. Furthermore, mass spectrometry-based proteomics showed an increase in
both EPHX1 and CYP2E1, as well as other indicators of ethanol induced hepatosteaosis in the
ethanol-treated groups [24]. This proteomic analysis also identified PHPT1 expression as being
significantly decreased in the treated samples by 2-fold. These results provided validation for
the model in that it created a diseased state organism that differed from the control. It also
allowed us to identify PHPT1 expression as significantly influenced following ethanol-induced
hepatosteosis, making it a potential player in the disease onset. To further investigate this, we
developed a PHPT1 liver-specific overexpression model and a PHPT1 knockout model.
PHPT1 overexpression was accomplished using an adenoviral-based vector coded with
PHPT1 and an albumin promoter. This experiment was done in comparison to the same
construct but with an eGFP sequence for amplification instead of PHPT1. This virus was
injected intravenously with an albumin promoter for targeted expression in the liver. C57BL/J6
mice were sacrificed 5-days following injection to verify expression change. EGFP expression
was verified using microscopy, ELISA, and mass spectrometry-based proteomics. PHPT1 levels
were verified using western blot and proteomics as well. Expression levels were compared
between tissue types (liver and spleen) to determine organ specificity, and between constructs
(eGFP and PHPT1). EGFP expression was only identified in the Ad-eGFP animal’s liver through
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proteomic analyses and ELISA. Microscopy showed no expression of eGFP in the PHPT1 livers
or in other tissues such as the spleen. PHPT1 expression was shown to be increased 3-fold in
liver tissue compared to the Ad-GFP livers by western blot, and expression was increased 18fold as determined by proteomic analysis. PHPT1 expression in either cohort’s spleen tissue
remained the same.
The knockout PHPT1 model was requested from the UC Davis KOMP repository. This
mouse was genetically altered using Cre recombination to create a non-conditional knockout
lacZ gene in a C57BL/6J mouse. These mice showed heterozygous expression of PHPT1 and
the lacZ recombinant gene. Mice were bred over many generations, and they were genotyped
using PCR and phenotyped using western blot, to confirm expression profiles. Genotypes were
confirmed by PCR using a PHPT1 (WT) primer and a lacZ (KO) primer. Following multiple HetHet cross (N>20) and genotyping of each viable offspring (N=128), we identified no
homozygous knockouts. Using a chi-square test, we determined with a 99% confidence that this
inheritance pattern did not follow that of Mendelian genetics. We then validated protein
expression using western blot analysis of multiple tissue types to determine PHPT1 expression.
We found that PHPT1 expression was decreased by an average of approximately 50% in each
tissue analyzed from the heterozygous mice, as compared to the wild-type.
Following validation of the expression profiles, liver samples from each PHPT1
expression model were used for mass-spectrometry based phenotypic characterization. These
models were then compared to wild-type mice of the same age and origin. Expression changes
between each model and the complementary control model were then compared to determine
any consistencies between all three models (Wild-type, PHPT1 overexpression, and PHPT1
heterozygous). This investigation found a significant p-value of overlap with both the over
expression mouse model changes, and the heterozygous model changes, with upstream
regulators involved in hormone-regulated transcriptional activation and with a cell cycle
72

regulatory molecule. Although, p-value of overlap was significant for both expression models,
the proteins identified in each model that overlapped with the upstream regulator shared very
few similarities. This result suggests different mechanism being influenced by PHPT1
overexpression as compared to the knockout.
Furthermore, each expression model showed significant p-values of overlap with unique
canonical pathways. The targets predicted to be influenced by PHPT1 overexpression were
glycogen, and S-methyl-5'-thioadenosine degradation. These are both involved in preparation of
cell replication [134] and inflammatory pathways [135]. Overexpression also shows overlap with
α-tocopherol degradation, which signifies an increase in β-oxidation and excess antioxidant
production [108]. Alternatively, we see overlap in the heterozygous model with two pathways
signaling immune response-mediated cell death and the type 1 diabetes signaling pathway. The
identified pathways suggest that the PHPT1 overexpression cells are better suited for an
external stress, whereas the heterozygous cells seem to be undergoing a stress response
already, presumably induced by a decrease in PHPT1 expression.
Ethanol Studies
Following the development and characterization of the PHPT1 expression models, we
determined how PHPT1 expression is influencing the onset of ethanol-induced hepatic
steatosis. This investigation was carried out using the 10-day chronic plus binge ethanol
consumption model [77]. In each case, mice were pair-fed with a control which consumed a
dextrose supplemented diet without ethanol at a similar rate to that of the ethanol fed mouse.
These mice were immediately sacrificed 9 hours after the gavage given on the 10th day, and the
livers were removed for analysis. To determine the influence of PHPT1 on ethanol-induced liver
damage, each cohort underwent a variety of tests to determine the disease progression and the
changes in proteomic expression levels. We also, validated PHPT1 expression differences
between the models following the ethanol treatment using western blot, and proteomic analysis.
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First, treatment validation was performed by testing the BEC. In addition, clinical
chemistry of the mouse blood for circulating AST, ALT, and TAG levels was conducted to
determine the initial changes in liver function following ethanol and control treatments. We did
expect to see some increase in the control mice due to the high caloric intake, but the largest
increase should be in the ethanol fed mice. Next, disease progression was determined using
H&E staining and scoring for steatosis. Pair-fed mouse livers were selected for paraffinembedding and formalin-fixed for H&E staining. Slides were then analyzed for steatosis scoring
to determine the extent of ethanol-induced liver damage. Images of slides were taken as well, to
be scored and analyzed for steatosis markers, such as lipid droplet formation, hepatocyte
ballooning, and inflammation. Disease onset and treatment validation was also performed by
quantifying known proteomic markers. Furthermore, PHPT1 expression was validated using
western blot and LFQ intensity values from all samples. These data confirmed a consistent
difference in PHPT1 expression levels, regardless of treatment type, between models.
Additional expression validation was performed on the Ad-GFP samples using an ELISA, which
provided absolute quantification. ELISA data reiterated that time or treatment type did not
influence the expression of eGFP in the Ad-GFP samples.
Last, we performed mass spectrometry-based phenotypic characterization on all treated
samples from all the PHPT1 expression models. Significant differentially expressed proteins
were identified based on their LFQ intensity values and calculated using stringent statistical
filtering. Fold-changes of identified significantly changed proteins were then uploaded to IPA for
core analysis, to determine predicted regulators and canonical pathways influenced by PHPT1
expression. These results were compared between models, to determine differences in PHPT1
expression influence. Our results revealed that the PHPT1 heterozygous expression model is
predicted to inhibit PPARα/RXRα pathway, while activating integrin, CXCR, and RAC signaling
pathways. PPARα/RXRα inhibition would result in a decrease in fatty acid β-oxidation, which
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leads directly to increased lipid accumulation. In addition, activation of the integrin pathway
relates to cell signaling of many forms including adhesion, activation, or inflammation [130].
Whereas, Rac pathway activation leads to cytoskeletal rearrangement or cell cycle progression
[128], and CXCR activation is known to relate with immune response [129] and has been
associated with MYC-induced cancer progression [136]. This coincides with the predicted
activation of MYC in the heterozygous model, as well. MYC is a known oncogene [104] involved
in regulating cell survival pathways [123].
Alternatively, PHPT1 overexpression is predicted to activate the upstream regulator
NR1I3 and ABCB6. NR1I3 activation would increase the RXRβ pathway, increase production of
alcohol dehydrogenase, and is a protective protein during xenobiotic response [137]. Both
NR1I3 and ABCB6 are regulators of cytochrome P450s, which are essential in ethanol exposure
response [15, 121, 122, 124, 137]. The heterozygous PHPT1 model was predicted to inhibit
ABCB6 activation, thus decreasing the xenobiotic response. These prediction models along with
our disease phenotype data demonstrate that PHPT1 overexpression is playing a protective role
against ethanol-induced liver injury, and the PHPT1 heterozygous model is more susceptible to
liver damage.
Future directions
The completion of this study has brought about significant advances in understanding
the contribution of a poorly characterized protein in a novel role. In addition, this study has
provided new ways to investigate the enzymatic activity of PHPT1 and discovered, for the first
time to the best of our knowledge, that a PHPT1 complete knockout results in early embryonic
lethality. We have displayed a strong correlation with PHPT1 expression levels and
susceptibility to fatty liver disease develop that has never been published before. Finally, we
have suggested multiple novel pathways and mechanisms that phosphohistidine signaling is
influencing in mammalian cells. Although the accomplishments of this study are significant,
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there is much more to be done in order to fully understand the role of PHPT1 and
phosphohistidine signaling in the onset of ALD.
Additional Mouse models
Ideally, more animal studies would have been utilized to fully understand how and why
PHPT1 expression was influencing ethanol-induced liver injury. Our overexpression and
heterozygous mouse showed the extreme conditions of PHPT1 expression, but many more
questions are left to be answered following the investigation of these two models. Unfortunately,
a complete animal wide knockout was not possible due to the embryonic lethality of the allele.
However, it is possible to create a liver-specific siRNA-mediated knockout using an adenoviral
based vector. In addition, an investigation using the liver-specific overexpression vector on the
heterozygous model would show if a phenotypic rescue was possible. Furthermore, creation of
an enzymatically inactive PHPT1 overexpression model would aid in determining if PHPT1
phosphatase activity was influencing disease progression or if this was being done through an
alternative mechanism. The PHPT1 H52A mutant could be used in the viral construct just as in
the Ad-PHPT1 overexpression. In addition, creating a PHPT1 rescue model using the AdPHPT1 virus to rescue the heterozygous would assist further in linking PHPT1 expression to
ethanol-induced liver injury development. The means and materials to create these models and
characterize their phenotype before and after ethanol treatment is available [138], and they
would provide much greater insight into how phosphohistidine signaling is involved in injury
onset.
Lipidomic analysis
Given the significant overlap in PHPT1 expression and numerous lipid homeostasis
pathways, an in depth lipidomic analysis of tissues with varying PHPT1 expression and ethanol
treatment would provide critical insight into the mechanisms of phosphohistidine signaling. It is
already well known that lipid oxidation and metabolism are affected by chronic ethanol exposure
[17]. This effect occurs via a combination of ethanol-induced insults including that of ROS [11]
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and endoplasmic reticulum stress [13]. Oxidative stress combined with ethanol’s inhibition of
AMPK activation, leads to an increase in fatty acid and lipid production in hepatocytes, mediated
by SREBP1-C [13]. Concurrently, ethanol causes a decrease in fatty acid β-oxidation via
PPARα inhibition through oxidative stress [28]. This inhibition results in an increase in cellular
fatty acids and creates the hepatocyte ballooning effect and lipid droplet formation commonly
seen in liver histology [28]. This response is well characterized during chronic ethanol exposure;
however, our data suggests that PHPT1 is influencing this response.
Our PHPT1 expression characterization data suggests phosphohistidine signaling is
involved in key transcriptional regulatory pathways such a 17β-estradiol signaling, MYC
activation, and other hormonal signaling pathways (See Chapter 3: results). Based on the
ethanol studies (See Chapter 4: results), this seems to create a phenotype that is either better
prepared for ethanol stress, in the case of PHPT1 overexpression, or more susceptible to
development of steatosis, in our heterozygous model. This susceptibility was further shown by
predicted inhibition of pathways, such as the PPARα/RXRα in the heterozygous models, and
change in expression levels of key fatty acid metabolism enzymes, such as FABP4 and FABP5
in both models [139]. This overlap in PHPT1 expression levels with fatty acid metabolism
enzymes and pathways suggests phosphohistidine signaling influences lipid homeostasis,
following ethanol exposure. This trend was further validated by the steatosis scoring and
histological staining performed on treated tissues, which showed a significantly lower
development of steatosis for the tissues that were overexpressing PHPT1 than those at wildtype levels. In addition, histology showed tissues with the heterozygous genotype had greater
steatosis development and lipid droplet formation induced by an increased calorie diet alone in
the control groups. Tissues from mice treated with ethanol showed similar severity in damage
between the heterozygous and wild-type. To further understand how PHPT1 is influencing the
creation and regulation of these lipids, a lipidomic analysis of these tissues would be necessary.
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Shotgun lipidomics is similar in technique to shotgun proteomics, in that it analyzes
many forms of the biological molecule at one time [140]. This method would allow us to take a
snapshot of the types of lipids being expressed in our various models of PHPT1 expression and
disease state. This method is beneficial in that it would give us an idea as to which lipids are
being influenced and would provide direction to further investigate specific lipid families [141].
However, the limitations of this method coincide with its robustness. The highly complex lipid
molecules are often very abundant and usually lead to high degrees of overlap in parent ion
mass between multiple lipid types [142]. This makes it far more difficult to quantify a specific
conformation when no isolation or fractionation has occurred prior to analysis. The
implementation of shotgun lipidomics would be the first step in analysis, and it will determine
which lipid classes should be isolated for further investigation in each sample.
Following identification of lipid targets, ideally, we would be able to isolate and determine
expression changes in these targets between cohorts. Quantification would be accomplished
using parallel reaction monitoring (PRM) on the Q-Exactive hybrid Orbitrap instrument [126].
This instrument allows us to specify a parent ion mass and the product ions created from it by
fragmentation to monitor intensity levels and quantify lipid classes specifically. PRM allows us to
specify multiple parent ion targets (lipid classes) for quantification from the same sample
simultaneously [126]. Targeted lipidomics via PRM will provide reliable and reproducible
quantification of the lipids present in each sample to determine how their synthesis is influenced
in each cohort, and it will provide additional insight into the mechanism of phosphohistidine
signaling influencing lipid homeostasis.
Mechanistic Validation
The use of mass spectrometry to determine protein expression changes between
treatment groups is currently a widely excepted method among many scientific fields [76, 143147]. Instrumentation has advanced significantly over the past 20 years and provides highly
reliable and reproducible results, which can be further solidified by technical or biological
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replicates (See Chapter 1: Mass spectrometry-based proteomics). Regular instrumental
maintenance and internal controls and standards contributes significantly to generating high
resolution and high mass accuracy data. Samples should also be analyzed concurrently with
multiple replicates, quality controls, and blanks included before, during, and after the sequence
to maximize reproducibility. In addition, database search parameters should be set with high
stringencies and low mass tolerance variabilities, as well as low false discovery rates to further
insure high-resolution data is being correctly matched with the peptides and proteins they
originate from [76]. Furthermore, stringent unbiased statistical analysis following identification
decreases the false discovery rate, and accuracy is increased further by only accepting proteins
identified in a majority of the biological replicates from a single cohort. All of these steps are
taken in the previously described experimental methods (Chapter 3: Methods; Chapter 4:
Methods) to ensure high quality accurate data, reflecting a snapshot of the proteomes under
investigation. Thus, making western blot, or other validations of mass spectrometry-identified
protein expressions, complementary but not a necessity.
However, further validation of the predicted influenced pathways identified through IPA is
necessary to further understand the mechanisms being influenced by phosphohistidine
signaling, during chronic ethanol exposure. Many of the identified pathways or upstream
regulators are either regulated independently of protein expression, or instrumentation is not
able to identify them due their expression levels or the sample’s complexity. Regulation of this
type includes post translation modifications, conformational alterations, or ligand binding. All
mechanisms of regulation and specific protein expression can be verified using methods such
as western blot, phosphoproteomics, immunoprecipitation, and many other methods specific to
the regulatory element. Specifically, to verify the deactivation of the PPARα/RXRα pathway,
predicted to be inhibited in the heterozygous ethanol treated mice, a western blot could be used
to determine changes in PPARα expression levels as well as changes in one of the many
downstream targets of PPARα, such as FABP1 [148]. In addition, activation of PPARα/RXRα
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requires the formation of a heterodimer [137]. PPARα and RXRα co-localization can be
determined using immunohistochemistry via antibodies against each protein. Furthermore, fatty
acid β-oxidation is the downstream effect of PPARα/RXRα activation [149]. The levels of βoxidation can be measured to validate inhibition or activation using one of many fatty acid βoxidation assays available. Validation of all the predicted upstream regulators and pathways is
necessary to better understand the mechanisms of PHPT1 regulation.
Targeted search for phosphohistidine phosphatase proteins
It is apparent from our findings that PHPT1 and phosphohistidine signaling play a much
larger role in ethanol response in the liver than previously believed. It is very likely that this
novel role is mediated through previously unidentified targets of phosphohistidine regulation.
The next step in further understanding this mechanism is determining what proteins are directly
targeted by phosphohistidine and influenced by PHPT1 expression and activity. However,
identifying these targets in not an easy feat. The challenges of isolating and identifying
phosphohistidine modified proteins are still difficult to overcome, even with modern scientific
techniques. One improvement to the challenge, is the development of a pan-phosphohistidine
antibody, specific for N-1 or N-3 phosphohistidine modification[60]. Development of this
antibody was only made possible using a phosphohistidine analogs with higher stability than the
modification [150, 151]. The developed antibody claims to bind only to proteins with the
specified phosphohistidine modification (N-1 or N-3) [152]. This antibody has been tested in our
lab with some success. Therefore, if the targets are accurate, western blot analysis using this
antibody shows a great deal of phosphohistidine targets that have yet to be characterized.
There is also a potential for this antibody to be used in an immunoprecipitation experiment, to
isolate only those proteins that contain phosphohistidine modification. Proteins can then be
characterized using mass spectrometry-based proteomics to determine their identity.
Furthermore, an additional co-immunoprecipitation experiment can be performed using PHTP1
as the target and the identified phosphohistidine-containing proteins as the potential ligands.
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This experiment could help determine if any of these targets of phosphohistidine are also
targets of PHPT1. Confirmation of this type can be achieved for specific proteins using the mass
spectrometry-based phosphohistidine phosphatase assay, previously described in this text
(Appendix A: Scientific Reports). Furthermore, mass spectrometry methods have been
developed to identify phosphohistidine-modified proteins based on neutral losses during CID
[153]. Using this method, two novel sites of phosphohistidine modification including aldehydealcohol dehydrogenase were determined. This discovery potentially creates another link
between PHPT1 expression and chronic ethanol exposure.
Identifying novel targets of phosphohistidine and PHPT1 would be beneficial in not only
further understanding the role of phosphohistidine during ethanol exposure, but these targets
could also lead to a better understanding of the role of PHPT1 in normal cellular functions [60].
PHPT1 has been identified in numerous diseases, including cancers, but often the pathways
and mechanisms associated with its expression differ depending on the cell type [46, 66, 67,
112, 154]. These studies lead us to believe phosphohistidine signaling and PHTP1 regulation of
this modification is playing a diverse role in cellular functions. A better understanding of this role
would be accomplished by determining a more comprehensive list of phosphohistidine and
PHPT1 targets.
Human tissue analyses
The question of translational relevance is always considered when using any model. In
our case, the mouse model was the closest organism we could use for ethanol studies and still
be able to create the PHPT1 overexpression and heterozygous genotypes in a relatively short
time frame. However, human samples are always the end goal. Although altering the expression
levels and disease state of a human sample would not be possible, there are currently human
liver samples available which have known patient backgrounds and have developed varying
states of ALD. These tissues are available by request from the Ibrahim El-Hefni liver
biorepository and California Pacific Medical Center. Liver samples were taken from patients who
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had a range of ALDs varying from mild steatosis up to severe late stage hepatitis. A majority of
the samples, however, are from patients in the later stages and from individuals with
backgrounds of existing liver disease, or familial history, making them less likely to fit the
requirements for our study. This outcome is most likely due to the initial asymptomatic
progression of the disease, making early onset very difficult to detect unless an existing liver
disease is already present [11].
Nonetheless, human tissues could provide additional insight into the role of PHPT1 in
progression of human ALD. It would not be difficult to screen the expression levels of PHPT1 in
various disease states, and normal levels of PHPT1 expression in human liver tissue is already
available. The human tissue aspect of this investigation would be the final step in validating any
mechanism identified in the mouse model in human liver tissues. Therefore, although these
tissues are currently available, it would make most sense to obtain them following all previously
described experiments to make the most out of the sample provided. Human tissues could
immediately be screened for other targets of PHPT1 and phosphohistidine identified, and for
phosphohistidine modifications using the same methods described previously (Chapter 5:
targeted search for phosphohistidine phosphatase proteins). Human tissue analyses would
provide high confidence in terms of overall relevance of PHPT1 and phosphohistidine signaling
in ALD pathogenesis, and these samples would provide a novel avenue of study on the role of
phosphohistidine in mammalian cellular processes.

82

References
[1] Yoon, Y. H., Yi, H. Y., Liver cirrhosis and viral Hepatitis C infection mortality among Hispanic
subgroups in the United States, 1999-2003: A multiple cause analysis. Alcoholism-Clinical and
Experimental Research 2006, 30, 168a-168a.
[2] Szabo, G., Mandrekar, P., Focus On: Alcohol and the Liver. Alcohol Research & Health 2010, 33, 8796.
[3] Hanson, M., Preventing alcohol abuse: Alcohol, culture, and control - Hanson,DJ. J Soc Serv Res 1996,
21, 79-80.
[4] Lim, S. S., Vos, T., Flaxman, A. D., AlMazroa, M. A., Memish, Z. A., A comparative risk assessment of
burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 19902010: a systematic analysis for the Global Burden of Disease Study 2010 (vol 380, pg 2224, 2012). Lancet
2013, 381, 628-628.
[5] World Health Organization., Global status report on alcohol and health 2014, World Health
Organization, Geneva 2014.
[6] Forouzanfar, M. H., Afshin, A., Alexander, L. T., Anderson, H. R., et al., Global, regional, and national
comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or
clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet
2016, 388, 1659-1724.
[7] Schuckit, M. A., Alcohol-use disorders. Lancet 2009, 373, 492-501.
[8] Crabb, D. W., Pathogenesis of alcoholic liver disease: newer mechanisms of injury. Keio J Med 1999,
48, 184-188.
[9] MacSween, R. N., Scott, A. R., Hepatic cirrhosis: a clinico-pathological review of 520 cases. J Clin
Pathol 1973, 26, 936-942.
[10] Galambos, J. T., Natural history of alcoholic hepatitis. 3. Histological changes. Gastroenterology
1972, 63, 1026-1035.
[11] O'Shea, R. S., Dasarathy, S., McCullough, A. J., Alcoholic Liver Disease. Am J Gastroenterol 2010, 105,
14-32.
[12] Caballeria, J., Is there a role for pentoxifylline in the treatment of alcoholic hepatitis? Gastroenterol.
Hepatol. 2016, 39, 560-565.
[13] Gao, B., Bataller, R., Alcoholic Liver Disease: Pathogenesis and New Therapeutic Targets.
Gastroenterology 2011, 141, 1572-1585.
[14] Norberg, A., Jones, A. W., Hahn, R. G., Gabrielsson, J. L., Role of variability in explaining ethanol
pharmacokinetics - Research and forensic applications. Clin Pharmacokinet 2003, 42, 1-31.
[15] Cederbaum, A. I., Alcohol Metabolism. Clin Liver Dis 2012, 16, 667-+.
[16] Lieber, C. S., Alcohol: Its metabolism and interaction with nutrients. Annu Rev Nutr 2000, 20, 395-+.
[17] Lieber, C. S., Alcoholic fatty liver: its pathogenesis and mechanism of progression to inflammation
and fibrosis. Alcohol 2004, 34, 9-19.
[18] Cederbaum, A. I., Cytochrome P450 2E1-dependent oxidant stress and upregulation of anti-oxidant
defense in liver cells. J Gastroen Hepatol 2006, 21, S22-S25.
[19] Wheeler, M. D., Kono, H., Yin, M., Nakagami, M., et al., The role of Kupffer cell oxidant production
in early ethanol-induced liver disease. Free Radical Bio Med 2001, 31, 1544-1549.
83

[20] Fernandezcheca, J. C., Ookhtens, M., Kaplowitz, N., Effects of Chronic Ethanol Feeding on Rat
Hepatocytic Glutathione - Relationship of Cytosolic Glutathione to Efflux and Mitochondrial
Sequestration. J Clin Invest 1989, 83, 1247-1252.
[21] Fernandezcheca, J. C., Garciaruiz, C., Ookhtens, M., Kaplowitz, N., Impaired Uptake of Glutathione
by Hepatic Mitochondria from Chronic Ethanol-Fed Rats - Tracer Kinetic-Studies Invitro and Invivo and
Susceptibility to Oxidant Stress. J Clin Invest 1991, 87, 397-405.
[22] Hirano, T., Kaplowitz, N., Tsukamoto, H., Kamimura, S., Fernandezcheca, J. C., Hepatic Mitochondrial
Glutathione Depletion and Progression of Experimental Alcoholic Liver-Disease in Rats. Hepatology
1992, 16, 1423-1427.
[23] Wheeler, M. D., Nakagami, M., Bradford, B. U., Uesugi, T., et al., Overexpression of manganese
superoxide dismutase prevents alcohol-induced liver injury in the rat. Journal of Biological Chemistry
2001, 276, 36664-36672.
[24] Gong, P. F., Cederbaum, A. I., Nieto, N., Heme oxygenase-1 protects HEPG2 cells against cytochrome
P450 2E1-dependent toxicity. Free Radical Bio Med 2004, 36, 307-318.
[25] Malhi, H., Kaufman, R. J., Endoplasmic reticulum stress in liver disease. J Hepatol 2011, 54, 795-809.
[26] Ji, C., Deng, Q. G., Kaplowitz, N., Role of TNF-alpha in ethanol-induced hyperhomocysteinemia and
murine alcoholic liver injury. Hepatology 2004, 40, 442-451.
[27] Petrasek, J., Iracheta-Vellve, A., Csak, T., Satishchandran, A., et al., STING-IRF3 pathway links
endoplasmic reticulum stress with hepatocyte apoptosis in early alcoholic liver disease. Proceedings of
the National Academy of Sciences of the United States of America 2013, 110, 16544-16549.
[28] Crabb, D. W., Liangpunsakul, S., Alcohol and lipid metabolism. J Gastroen Hepatol 2006, 21, S56S60.
[29] Ji, C., Kaplowitz, N., Betaine decreases hyperhomocysteinemia, endoplasmic reticulum stress, and
liver injury in alcohol-fed mice. Gastroenterology 2003, 124, 1488-1499.
[30] Endo, M., Masaki, T., Seike, M., Yoshimatsu, H., TNF-alpha induces hepatic steatosis in mice by
enhancing gene expression of sterol regulatory element blinding protein-1c (SREBP-1c). Exp Biol Med
2007, 232, 614-621.
[31] Kang, L., Sebastian, B. M., Pritchard, M. T., Pratt, B. T., et al., Chronic ethanol-induced insulin
resistance is associated with macrophage infiltration into adipose tissue and altered expression of
adipocytokines. Alcoholism-Clinical and Experimental Research 2007, 31, 1581-1588.
[32] Fischer, M., You, M., Matsumoto, M., Crabb, D. W., Peroxisome proliferator-activated receptor
alpha ( PPAR alpha) agonist treatment reverses PPAR alpha dysfunction and abnormalities in hepatic
lipid metabolism in ethanol-fed mice. Journal of Biological Chemistry 2003, 278, 27997-28004.
[33] Molina, P. E., Alcohol - intoxicating roadblocks and bottlenecks in hepatic protein and lipid
metabolism. American Journal of Physiology-Endocrinology and Metabolism 2008, 295, E1-E2.
[34] Zhou, G. C., Myers, R., Li, Y., Chen, Y. L., et al., Role of AMP-activated protein kinase in mechanism
of metformin action. J Clin Invest 2001, 108, 1167-1174.
[35] Klumpp, S., Bechmann, G., Maurer, A., Selke, D., Krieglstein, J., ATP-citrate lyase as a substrate of
protein histidine phosphatase in vertebrates. Biochemical and biophysical research communications
2003, 306, 110-115.
[36] Boyer, P. D., Deluca, M., Ebner, K. E., Hultquist, D. E., Peter, J. B., Identification of phosphohistidine
in digests from a probable intermediate of oxidative phosphorylation. The Journal of biological chemistry
1962, 237, PC3306-PC3308.
[37] Maurer, A., Wieland, T., Meissl, F., Niroomand, F., et al., The beta-subunit of G proteins is a
substrate of protein histidine phosphatase. Biochemical and biophysical research communications 2005,
334, 1115-1120.

84

[38] Fujitaki, J. M., Fung, G., Oh, E. Y., Smith, R. A., Characterization of Chemical and Enzymatic AcidLabile Phosphorylation of Histone H-4 Using P-31 Nuclear Magnetic-Resonance. Biochemistry 1981, 20,
3658-3664.
[39] Srivastava, S., Zhdanova, O., Di, L., Li, Z., et al., Protein histidine phosphatase 1 negatively regulates
CD4 T cells by inhibiting the K(+) channel KCa3.1. Proceedings of the National Academy of Sciences of the
United States of America 2008, 105, 14442-14446.
[40] Wagner, P. D., Vu, N. D., Phosphorylation of ATP-citrate lyase by nucleoside diphosphate kinase.
The Journal of biological chemistry 1995, 270, 21758-21764.
[41] Ek, P., Pettersson, G., Ek, B., Gong, F., et al., Identification and characterization of a mammalian 14kDa phosphohistidine phosphatase. European journal of biochemistry / FEBS 2002, 269, 5016-5023.
[42] Panda, S., Srivastava, S., Li, Z., Vaeth, M., et al., Identification of PGAM5 as a Mammalian Protein
Histidine Phosphatase that Plays a Central Role to Negatively Regulate CD4(+) T Cells. Molecular Cell
2016, 63, 457-469.
[43] Attwood, P. V., Ludwig, K., Bergander, K., Besant, P. G., et al., Chemical phosphorylation of histidinecontaining peptides based on the sequence of histone H4 and their dephosphorylation by protein
histidine phosphatase. Bba-Proteins Proteom 2010, 1804, 199-205.
[44] Ek, P., Ek, B., Zetterqvist, O., Phosphohistidine phosphatase 1 (PHPT1) also dephosphorylates
phospholysine of chemically phosphorylated histone H1 and polylysine. Upsala journal of medical
sciences 2015, 120, 20-27.
[45] Krieglstein, J., Lehmann, M., Maeurer, A., Gudermann, T., et al., Reduced viability of neuronal cells
after overexpression of protein histidine phosphatase. Neurochemistry international 2008, 53, 132-136.
[46] Kamath, V., Kyathanahalli, C. N., Jayaram, B., Syed, I., et al., Regulation of glucose- and
mitochondrial fuel-induced insulin secretion by a cytosolic protein histidine phosphatase in pancreatic
beta-cells. American Journal of Physiology-Endocrinology and Metabolism 2010, 299, E276-E286.
[47] Cuello, F., Schulze, R. A., Heemeyer, F., Meyer, H. E., et al., Activation of heterotrimeric G proteins
by a high energy phosphate transfer via nucleoside diphosphate kinase (NDPK) B and G beta subunits Complex formation of NDPK B with G beta gamma dimers and phosphorylation of His-266 in G beta.
Journal of Biological Chemistry 2003, 278, 7220-7226.
[48] Beckman-Sundh, U., Ek, B., Zetterqvist, O., Ek, P., A screening method for phosphohistidine
phosphatase 1 activity. Upsala journal of medical sciences 2011, 116, 161-168.
[49] Yanicostas, C., Vincent, A., Lepesant, J. A., Transcriptional and Posttranscriptional Regulation
Contributes to the Sex-Regulated Expression of 2 Sequence-Related Genes at the Janus Locus of
Drosophila-Melanogaster. Mol Cell Biol 1989, 9, 2526-2535.
[50] Yao, D. B., Peng, S. L., Dai, C. L., The role of hepatocyte nuclear factor 4alpha in metastatic tumor
formation of hepatocellular carcinoma and its close relationship with the mesenchymal-epithelial
transition markers. Bmc Cancer 2013, 13.
[51] Xu, A., Hao, J., Zhang, Z., Tian, T., et al., 14-kDa phosphohistidine phosphatase and its role in human
lung cancer cell migration and invasion. Lung cancer 2010, 67, 48-56.
[52] Han, S. X., Wang, L. J., Zhao, J., Zhang, Y., et al., 14-kDa Phosphohistidine phosphatase plays an
important role in hepatocellular carcinoma cell proliferation. Oncology letters 2012, 4, 658-664.
[53] Sharma, S., Ray, S., Mukherjee, S., Moiyadi, A., et al., Multipronged quantitative proteomic analyses
indicate modulation of various signal transduction pathways in human meningiomas. Proteomics 2015,
15, 394-407.
[54] Matthews, H. R., Pesis, K., Kim, Y. K., Protein Histidine Phosphatase-Activity of Protein Phosphatase1, Phosphatase-2a and Phosphatase-2c and Inhibition by Okadaic Acid. Faseb Journal 1995, 9, A1347A1347.
[55] Hunter, T., Sefton, B. M., Transforming Gene-Product of Rous-Sarcoma Virus Phosphorylates
Tyrosine. P Natl Acad Sci-Biol 1980, 77, 1311-1315.
85

[56] Attwood, P. V., Piggott, M. J., Zu, X. L., Besant, P. G., Focus on phosphohistidine. Amino acids 2007,
32, 145-156.
[57] Busam, R. D., Thorsell, A. G., Flores, A., Hammarstrom, M., et al., First structure of a eukaryotic
phosphohistidine phosphatase. The Journal of biological chemistry 2006, 281, 33830-33834.
[58] Schaller, G. E., Histidine kinases and the role of two-component systems in plants. Advances in
Botanical Research Incorporating Advances in Plant Pathology, Vol 32: Plant Protein Kinases 2000, 32,
109-148.
[59] Attwood, P. V., Histidine kinases from bacteria to humans. Biochemical Society transactions 2013,
41, 1023-1028.
[60] Piggott, M. J., Attwood, P. V., Post-translational modifications: Panning for phosphohistidine.
Nature chemical biology 2013, 9, 411-412.
[61] Tan, E. L., Besant, P. G., Zu, X. L., Turck, C. W., et al., Histone H4 histidine kinase displays the
expression pattern of a liver oncodevelopmental marker. Carcinogenesis 2004, 25, 2083-2088.
[62] Gong, W., Li, Y., Cui, G., Hu, J., et al., Solution structure and catalytic mechanism of human protein
histidine phosphatase 1. The Biochemical journal 2009, 418, 337-344.
[63] Ma, R., Kanders, E., Sundh, U. B., Geng, M., et al., Mutational study of human phosphohistidine
phosphatase: effect on enzymatic activity. Biochemical and biophysical research communications 2005,
337, 887-891.
[64] Gauci, S., Helbig, A. O., Slijper, M., Krijgsveld, J., et al., Lys-N and Trypsin Cover Complementary
Parts of the Phosphoproteome in a Refined SCX-Based Approach. Analytical Chemistry 2009, 81, 44934501.
[65] Martin, D. R., Dutta, P., Mahajan, S., Varma, S., Stevens, S. M., Jr., Structural and activity
characterization of human PHPT1 after oxidative modification. Sci Rep 2016, 6, 23658.
[66] Xu, A. J., Xia, X. H., Du, S. T., Gu, J. C., Clinical significance of PHPT1 protein expression in lung
cancer. Chinese Medical Journal 2010, 123, 3247-3251.
[67] Xu, A., Li, X., Wu, S., Lv, T., et al., Knockdown of 14-kDa phosphohistidine phosphatase expression
suppresses lung cancer cell growth in vivo possibly through inhibition of NF-kappa B signaling pathway.
Neoplasma 2016, 63, 540-547.
[68] Bolotin, E., Liao, H. L., Ta, T. C., Yang, C. H., et al., Integrated Approach for the Identification of
Human Hepatocyte Nuclear Factor 4 alpha Target Genes Using Protein Binding Microarrays. Hepatology
2010, 51, 642-653.
[69] Wisely, G. B., Miller, A. B., Davis, R. G., Thornquest, A. D., et al., Hepatocyte nuclear factor 4 is a
transcription factor that constitutively binds fatty acids. Structure 2002, 10, 1225-1234.
[70] Iwazaki, N., Kobayashi, K., Morimoto, K., Hirano, M., et al., Involvement of hepatocyte nuclear
factor 4alpha in transcriptional regulation of the human pregnane X receptor gene in the human liver.
Drug Metab Pharmacok 2008, 23, 59-66.
[71] Martinez-Jimenez, C. P., Kyrmizi, I., Cardot, P., Gonzalez, F. J., Talianidis, I., Hepatocyte Nuclear
Factor 4 alpha Coordinates a Transcription Factor Network Regulating Hepatic Fatty Acid Metabolism.
Mol Cell Biol 2010, 30, 565-577.
[72] Wieland, T., Hippe, H. J., Ludwig, K., Zhou, X. B., et al., in: Simon, M. I., Crane, B. R., Crane, A. (Eds.),
Methods in Enzymology, Vol 471: Two-Component Signaling Systems, Part C, Elsevier Academic Press
Inc, San Diego 2010, pp. 379-402.
[73] Postel, E. H., Berberich, S. J., Flint, S. J., Ferrone, C. A., Human c-myc transcription factor puf
identified as nm23-h2 nucleoside diphosphate kinase, a candidate suppressor of tumor-metastasis.
Science 1993, 261, 478-480.
[74] Ma, S. G., Zhu, M. S., Recent advances in applications of liquid chromatography-tandem mass
spectrometry to the ana lysis of reactive drug metabolites. Chem-Biol Interact 2009, 179, 25-37.

86

[75] Wisniewski, J. R., Zougman, A., Nagaraj, N., Mann, M., Universal sample preparation method for
proteome analysis. Nat Methods 2009, 6, 359-U360.
[76] Cox, J., Hein, M. Y., Luber, C. A., Paron, I., et al., Accurate Proteome-wide Label-free Quantification
by Delayed Normalization and Maximal Peptide Ratio Extraction, Termed MaxLFQ. Molecular & Cellular
Proteomics 2014, 13, 2513-2526.
[77] Bertola, A., Mathews, S., Ki, S. H., Wang, H., Gao, B., Mouse model of chronic and binge ethanol
feeding (the NIAAA model). Nat Protoc 2013, 8, 627-637.
[78] Mayfield, J., Arends, M. A., Harris, R. A., Blednov, Y. A., in: Bell, R. L., Rahman, S. (Eds.), Animal
Models for Medications Screening to Treat Addiction, Elsevier Academic Press Inc, San Diego 2016, pp.
293-355.
[79] Levine, R. L., Berlett, B. S., Moskovitz, J., Mosoni, L., Stadtman, E. R., Methionine residues may
protect proteins from critical oxidative damage. Mechanisms of Ageing and Development 1999, 107,
323-332.
[80] Reddy, V. Y., Desrochers, P. E., Pizzo, S. V., Gonias, S. L., et al., Oxidative Dissociation of Human
Alpha(2)-Macroglobulin Tetramers into Dysfunctional Dimers. Journal of Biological Chemistry 1994, 269,
4683-4691.
[81] Kanayama, A., Inoue, J., Sugita-Konishi, Y., Shimizu, M., Miyamoto, Y., Oxidation of I kappa B alpha
at methionine 45 is one cause of taurine chloramine-induced inhibition of NF-kappa B activation. Journal
of Biological Chemistry 2002, 277, 24049-24056.
[82] Bartlett, R. K., Urbauer, R. J. B., Anbanandam, A., Smallwood, H. S., et al., Oxidation of Met(144) and
Met(145) in calmodulin blocks calmodulin dependent activation of the plasma membrane Ca-ATPase.
Biochemistry 2003, 42, 3231-3238.
[83] Tuma, D., Casey, C., Dangerous byproducts of alcohol breakdown - Focus on adducts. Alcohol
Research & Health 2003, 27, 285-290.
[84] Deleve, L. D., Kaplowitz, N., Glutathione Metabolism and Its Role in Hepatotoxicity. Pharmacol
Therapeut 1991, 52, 287-305.
[85] Shepard, B. D., Tuma, P. L., Alcohol-induced protein hyperacetylation: mechanisms and
consequences. World journal of gastroenterology : WJG 2009, 15, 1219-1230.
[86] Chang, L. F., Karin, M., Mammalian MAP kinase signalling cascades. Nature 2001, 410, 37-40.
[87] Matthews, H. R., Protein-Kinases and Phosphatases That Act on Histidine, Lysine, or Arginine
Residues in Eukaryotic Proteins - a Possible Regulator of the Mitogen-Activated Protein-Kinase Cascade.
Pharmacol Therapeut 1995, 67, 323-350.
[88] Aksnes, H., Hole, K., Arnesen, T., in: Jeon, K. W. (Ed.), International Review of Cell and Molecular
Biology, Vol 316, Elsevier Academic Press Inc, San Diego 2015, pp. 267-305.
[89] Fernandezcheca, J. C., Hirano, T., Tsukamoto, H., Kaplowitz, N., Mitochondrial Glutathione
Depletion in Alcoholic Liver-Disease. Alcohol 1993, 10, 469-475.
[90] Cederbaum, A. I., CYP2E1 - Biochemical and toxicological aspects and role in alcohol-induced liver
injury. Mt Sinai J Med 2006, 73, 657-672.
[91] Lieber, C. S., CYP2E1: from ASH to NASH. Hepatol Res 2004, 28, 1-11.
[92] Dai, Y., Rashbastep, J., Cederbaum, A. I., Stable expression of human cytochrome-p4502e1 in hepg2
cells - characterization of catalytic activities and production of reactive oxygen intermediates.
Biochemistry 1993, 32, 6928-6937.
[93] Yin, D., Kuczera, K., Squier, T. C., The sensitivity of carboxyl-terminal methionines in calmodulin
isoforms to oxidation by H2O2 modulates the ability to activate the plasma membrane Ca-ATPase.
Chemical Research in Toxicology 2000, 13, 103-110.
[94] Bell-Temin, H., Zhang, P., You, M., Liu, B., Stevens, S. M., Novel Insights into Ethanol-Induced
Microglia Response Using Silac-Based Proteomics. Alcoholism-Clinical and Experimental Research 2013,
37, 127a-127a.
87

[95] Schumacher, B., van der Pluijm, I., Moorhouse, M. J., Kosteas, T., et al., Delayed and accelerated
aging share common longevity assurance mechanisms. Plos Genet 2008, 4, e1000161.
[96] Wei, Y. F., Matthews, H. R., Identification of phosphohistidine in proteins and purification of
protein-histidine kinases. Methods in enzymology 1991, 200, 388-414.
[97] Peter, J. B., Hultquist, D. E., Deluca, M., Boyer, P. D., Kreil, G., Bound Phosphohistidine as an
Intermediate in a Phosphorylation Reaction of Oxidative Phosphorylation Catalyzed by Mitochondrial
Extracts. Journal of Biological Chemistry 1963, 238, 1182-&.
[98] Wilson, C. G., Schupp, M., Burkhardt, B. R., Wu, J. M., et al., Liver-Specific Overexpression of
Pancreatic-Derived Factor (PANDER) Induces Fasting Hyperglycemia in Mice. Endocrinology 2010, 151,
5174-5184.
[99] Ramus, C., Hovasse, A., Marcellin, M., Hesse, A. M., et al., Benchmarking quantitative label-free LCMS data processing workflows using a complex spiked proteomic standard dataset. J Proteomics 2016,
132, 51-62.
[100] Marijanovic, Z., Laubner, D., Moller, G., Gege, C., et al., Closing the gap: I dentification of human 3ketosteroid reductase, the last unknown enzyme of mammalian cholesterol biosynthesis. Mol Endocrinol
2003, 17, 1715-1725.
[101] Evan, G. I., Wyllie, A. H., Gilbert, C. S., Littlewood, T. D., et al., Induction of apoptosis in fibroblasts
by c-myc protein. Cell 1992, 69, 119-128.
[102] Marino, M., Galluzzo, P., Ascenzi, P., Estrogen signaling multiple pathways to impact gene
transcription. Curr. Genomics 2006, 7, 497-508.
[103] Shehu, A., Albarracin, C., Devi, Y. S., Luther, K., et al., The Stimulation of HSD17B7 Expression by
Estradiol Provides a Powerful Feed-Forward Mechanism for Estradiol Biosynthesis in Breast Cancer Cells.
Mol Endocrinol 2011, 25, 754-766.
[104] Mukherjee, B., Morgenbesser, S. D., Depinho, R. A., Myc family oncoproteins function through a
common pathway to transform normal-cells in culture - cross-interference by max and trans-acting
dominant mutants. Genes & Development 1992, 6, 1480-1492.
[105] Wu, D. F., Cederbaum, A. I., Opposite action of S-adenosyl methionine and its metabolites on
CYP2E1-mediated toxicity in pyrazole-induced rat hepatocytes and HepG2 E47 cells. Am J Physiol-Gastr L
2006, 290, G674-G684.
[106] Guillou, V., Plourde-Owobi, L., Parrou, J. L., Goma, G., Francois, J., Role of reserve carbohydrates in
the growth dynamics of Saccharomyces cerevisiae. FEMS Yeast Res. 2004, 4, 773-787.
[107] Mustacich, D. J., Bruno, R. S., Traber, M. G., Vitamin E. Vitam Horm 2007, 76, 1-21.
[108] Mustacich, D. J., Leonard, S. W., Patel, N. K., Traber, M. G., alpha-tocopherol beta-oxidation
localized to rat liver mitochondria. Free Radical Bio Med 2010, 48, 73-81.
[109] Wang, L., Zheng, Y. S., Gao, X. X., Liu, Y. C., You, X. Q., Retinoid X receptor ligand regulates RXR
alpha/Nur77-dependent apoptosis via modulating its nuclear export and mitochondrial targeting.
International Journal of Clinical and Experimental Pathology 2017, 10, 10770-+.
[110] Berggre, P. O., Signal-transduction in type 1 diabetes mellitus. Horm. Res. 2008, 70, 1-2.
[111] Liadis, N., Murakami, K., Eweida, M., Elford, A. R., et al., Caspase-3-dependent beta-cell apoptosis
in the initiation of autoimmune diabetes mellitus. Mol Cell Biol 2005, 25, 3620-3629.
[112] Shen, H. L., Yang, P. Q., Liu, Q. J., Tian, Y., Nuclear expression and clinical significance of
phosphohistidine phosphatase 1 in clear-cell renal cell carcinoma. J. Int. Med. Res. 2015, 43, 747-757.
[113] Dicker, E., Cederbaum, A. I., Potter, B. J., Cultured Rat Hepatocytes as a Model for Alcohol
Metabolism. Hepatology 1986, 6, 1191-1191.
[114] Rhodes, J. S., Best, K., Belknap, J. K., Finn, D. A., Crabbe, J. C., Evaluation of a simple model of
ethanol drinking to intoxication in C57BL/6J mice. Physiology & Behavior 2005, 84, 53-63.

88

[115] Rath, M., Nguyen, T. G., Peris, J., McLaughlin, J. P., et al., Characterization of a gelatin-based
drinking in the dark mouse model of ethanol dependence: Role of microglia. Alcoholism-Clinical and
Experimental Research 2017, 41, 34A-34A.
[116] Simms, J. A., Steensland, P., Medina, B., Abernathy, K. E., et al., Intermittent access to 20% ethanol
induces high ethanol consumption in Long-Evans and Wistar rats. Alcoholism-Clinical and Experimental
Research 2008, 32, 1816-1823.
[117] Becker, H. C., Lopez, M. F., Increased ethanol drinking after repeated chronic ethanol exposure
and withdrawal experience in C57BL/6 mice. Alcoholism-Clinical and Experimental Research 2004, 28,
1829-1838.
[118] Conigrave, K. M., Davies, P., Haber, P., Whitfield, J. B., Traditional markers of excessive alcohol use.
Addiction 2003, 98, 31-43.
[119] Nan, Y. M., Kong, L. B., Ren, W. G., Wang, R. Q., et al., Activation of peroxisome proliferator
activated receptor alpha ameliorates ethanol mediated liver fibrosis in mice. Lipids Health Dis 2013, 12.
[120] Gong, P. F., Cederbaum, A. I., Nrf2 is increased by CYP2E1 in rodent liver and HepG2 cells and
protects against oxidative stress caused by CYP2E1. Hepatology 2006, 43, 144-153.
[121] Krishnamurthy, P. C., Du, G. Q., Fukuda, Y., Sun, D. X., et al., Identification of a mammalian
mitochondrial porphyrin transporter. Nature 2006, 443, 586-589.
[122] Boswell-Casteel, R. C., Fukuda, Y., Schuetz, J. D., ABCB6, an ABC Transporter Impacting Drug
Response and Disease. Aaps J. 2018, 20.
[123] Nilsson, J. A., Cleveland, J. L., Myc pathways provoking cell suicide and cancer. Oncogene 2003, 22,
9007-9021.
[124] Wang, Y. M., Ong, S. S., Chai, S. C., Chen, T. S., Role of CAR and PXR in xenobiotic sensing and
metabolism. Expert Opinion on Drug Metabolism & Toxicology 2012, 8, 803-817.
[125] Ronsein, G. E., Pamir, N., von Haller, P. D., Kim, D. S., et al., Parallel reaction monitoring (PRM) and
selected reaction monitoring (SRM) exhibit comparable linearity, dynamic range and precision for
targeted quantitative HDL proteomics. J Proteomics 2015, 113, 388-399.
[126] Rauniyar, N., Parallel Reaction Monitoring: A Targeted Experiment Performed Using High
Resolution and High Mass Accuracy Mass Spectrometry. Int J Mol Sci 2015, 16, 28566-28581.
[127] Galli, A., Pinaire, J., Fischer, M., Dorris, R., Crabb, D. W., The transcriptional and DNA binding
activity of peroxisome proliferator-activated receptor alpha is inhibited by ethanol metabolism - A novel
mechanism for the development of ethanol-induced fatty liver. Journal of Biological Chemistry 2001,
276, 68-75.
[128] Arneson, L. N., Leibson, P. J., Signaling in Natural Immunity: Natural Killer Cells. Neuroimmune
2005, 5, 151-166.
[129] Busillo, J. M., Benovic, J. L., Regulation of CXCR4 signaling. Bba-Biomembranes 2007, 1768, 952963.
[130] Harburger, D. S., Calderwood, D. A., Integrin signalling at a glance. J Cell Sci 2009, 122, 159-163.
[131] Brenner, C., Galluzzi, L., Kepp, O., Kroemer, G., Decoding cell death signals in liver inflammation. J
Hepatol 2013, 59, 583-594.
[132] Polireddy, K., Chavan, H., Abdulkarim, B. A., Krishnamurthy, P., Functional significance of the ATPbinding cassette transporter B6 in hepatocellular carcinoma. Mol Oncol 2011, 5, 410-425.
[133] Yin, H. Q., Kim, M., Kim, J. H., Kong, G., et al., Differential gene expression and lipid metabolism in
fatty liver induced by acute ethanol treatment in mice. Toxicol Appl Pharm 2007, 223, 225-233.
[134] Sekiya, S., Suzuki, A., Glycogen synthase kinase 3 beta-dependent Snail degradation directs
hepatocyte proliferation in normal liver regeneration. Proceedings of the National Academy of Sciences
of the United States of America 2011, 108, 11175-11180.
[135] Hevia, H., Varela-Rey, M., Corrales, F. J., Berasain, C., et al., 5 '-methylthioadenosine modulates the
inflammatory response to endotoxin in mice and in rat hepatocytes. Hepatology 2004, 39, 1088-1098.
89

[136] Saha, A., Ahn, S., Blando, J., Su, F., et al., Proinflammatory CXCL12-CXCR4/CXCR7 Signaling Axis
Drives Myc-Induced Prostate Cancer in Obese Mice. Cancer Res 2017, 77, 5158-5168.
[137] Waxman, D. J., P450 gene induction by structurally diverse xenochemicals: Central role of nuclear
receptors CAR, PXR, and PPAR. Archives of biochemistry and biophysics 1999, 369, 11-23.
[138] Shan, G., RNA interference as a gene knockdown technique. International Journal of Biochemistry
& Cell Biology 2010, 42, 1243-1251.
[139] Tan, N. S., Shaw, N. S., Vinckenbosch, N., Liu, P., et al., Selective cooperation between fatty acid
binding proteins and peroxisome proliferator-activated receptors in regulating transcription. Mol Cell
Biol 2002, 22, 5114-5127.
[140] Schwudke, D., Liebisch, G., Herzog, R., Schmitz, G., Shevchenko, A., Shotgun lipidomics by tandem
mass spectrometry under data-dependent acquisition control. Lipidomics and Bioactive Lipids 2007, 433,
175-+.
[141] Jung, H. R., Sylvanne, T., Koistinen, K. M., Tarasov, K., et al., High throughput quantitative
molecular lipidomics. Biochimica et biophysica acta 2011, 1811, 925-934.
[142] Li, M., Zhou, Z. G., Nie, H. G., Bai, Y., Liu, H. W., Recent advances of chromatography and mass
spectrometry in lipidomics. Analytical and bioanalytical chemistry 2011, 399, 243-249.
[143] Zhang, W., Progress in Mass Spectrometry Acquisition Approach for Quantitative Proteomics.
Chinese J Anal Chem 2014, 42, 1859-1868.
[144] Prakash, A., Peterman, S., Ahmad, S., Sarracino, D., et al., Hybrid Data Acquisition and Processing
Strategies with Increased Throughput and Selectivity: pSMART Analysis for Global Qualitative and
Quantitative Analysis. Journal of Proteome Research 2014, 13, 5415-5430.
[145] Kleparnik, K., Recent advances in combination of capillary electrophoresis with mass spectrometry:
Methodology and theory. Electrophoresis 2015, 36, 159-178.
[146] Tyanova, S., Temu, T., Sinitcyn, P., Carlson, A., et al., The Perseus computational platform for
comprehensive analysis of (prote)omics data. Nat Methods 2016, 13, 731-740.
[147] Aebersold, R., Mann, M., Mass-spectrometric exploration of proteome structure and function.
Nature 2016, 537, 347-355.
[148] Guzman, C., Benet, M., Pisonero-Vaquero, S., Moya, M., et al., The human liver fatty acid binding
protein (FABP1) gene is activated by FOXA1 and PPAR alpha; and repressed by C/EBP alpha: Implications
in FABP1 down-regulation in nonalcoholic fatty liver disease. Biochimica Et Biophysica Acta-Molecular
and Cell Biology of Lipids 2013, 1831, 803-818.
[149] Green, S., PPAR: A mediator of peroxisome proliferator action. Mutat. Res.-Fundam. Mol. Mech.
Mutagen. 1995, 333, 101-109.
[150] Mukai, S., Flematti, G. R., Byrne, L. T., Besant, P. G., et al., Stable triazolylphosphonate analogues
of phosphohistidine. Amino acids 2012, 43, 857-874.
[151] Kee, J. M., Oslund, R. C., Couvillon, A. D., Muir, T. W., A Second-Generation Phosphohistidine
Analog for Production of Phosphohistidine Antibodies. Organic letters 2015, 17, 187-189.
[152] Kee, J. M., Oslund, R. C., Perlman, D. H., Muir, T. W., A pan-specific antibody for direct detection of
protein histidine phosphorylation. Nature chemical biology 2013, 9, 416-U428.
[153] Oslund, R. C., Kee, J. M., Couvillon, A. D., Bhatia, V. N., et al., A phosphohistidine proteomics
strategy based on elucidation of a unique gas-phase phosphopeptide fragmentation mechanism. Journal
of the American Chemical Society 2014, 136, 12899-12911.
[154] Cai, X. J., Srivastava, S., Surindran, S., Li, Z., Skolnik, E. Y., Regulation of the epithelial Ca2+ channel
TRPV5 by reversible histidine phosphorylation mediated by NDPK-B and PHPT1. Mol Biol Cell 2014, 25,
1244-1250.

90

Appendix A – Nature: Scientific Reports

91

92

93

94

95

96

97

98

99

100

101

102

103

Appendix B – Nature: Scientific Reports, Supporting Information

104

105

106

Appendix C – Scientific Reports: Permissions

107

108

